Title: Bio-Engineered Skin and Soft Tissue Substitutes

See Also:  
- Amniotic Membrane and Amniotic Fluid medical policy  
- Periodontal Soft Tissue Grafting dental policy

<table>
<thead>
<tr>
<th>Professional</th>
<th>Institutional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Effective Date: February 13, 2007</td>
<td>Original Effective Date: December 15, 2008</td>
</tr>
<tr>
<td>Revision Date(s): May 21, 2008, August 3, 2010; March 1, 2012; January 15, 2013; December 12, 2013; January 1, 2014; April 30, 2015; May 1, 2016; March 20, 2017; April 19, 2017; July 18, 2018</td>
<td>Revision Date(s): September 2, 2010; March 1, 2012; January 15, 2013; December 12, 2013; January 1, 2014; April 30, 2015; May 1, 2016; March 20, 2017; April 19, 2017; July 18, 2018; January 1, 2019; November 26, 2019</td>
</tr>
<tr>
<td>Current Effective Date: November 26, 2019</td>
<td>Current Effective Date: November 26, 2019</td>
</tr>
</tbody>
</table>

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact Blue Cross and Blue Shield of Kansas Customer Service.

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
</table>
| Individuals:  
- Who are undergoing breast reconstruction | Interventions of interest are:  
- Allogeneic acellular dermal matrix products | Comparators of interest are:  
- Breast reconstruction without an acellular dermal matrix product | Relevant outcomes include:  
- Symptoms  
- Morbid events  
- Functional outcomes  
- Quality of life  
- Treatment-related morbidity |
<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals: • Who are undergoing tendon repair</td>
<td>Interventions of interest are: • Graftjacket</td>
<td>Comparators of interest are: • Surgical repair alone</td>
<td>Relevant outcomes include: • Symptoms • Morbid events • Functional outcomes • Quality of life • Treatment-related morbidity</td>
</tr>
<tr>
<td>Individuals: • Who are undergoing surgical repair of hernias or parastomal reinforcement</td>
<td>Interventions of interest are: • Acellular collagen-based scaffolds</td>
<td>Comparators of interest are: • Surgical repair alone • Standard surgical mesh</td>
<td>Relevant outcomes include: • Symptoms • Morbid events • Functional outcomes • Quality of life • Treatment-related morbidity</td>
</tr>
<tr>
<td>Individuals: • With diabetic lower-extremity ulcers</td>
<td>Interventions of interest are: • Apligraf, Dermagraft, AlloPatch, or Integra</td>
<td>Comparators of interest are: • Standard wound care</td>
<td>Relevant outcomes include: • Disease-specific survival • Symptoms • Change in disease status • Morbid events • Quality of life</td>
</tr>
<tr>
<td>Individuals: • With diabetic lower-extremity ulcers</td>
<td>Interventions of interest are: • Acellular dermal matrix products other than, Apligraf, Dermagraft, AlloPatch or Integra</td>
<td>Comparators of interest are: • Standard wound care</td>
<td>Relevant outcomes include: • Disease-specific survival • Symptoms • Change in disease status • Morbid events • Quality of life</td>
</tr>
<tr>
<td>Individuals: • With lower-extremity ulcers due to venous insufficiency</td>
<td>Interventions of interest are: • Apligraf and Oasis Wound Matrix</td>
<td>Comparators of interest are: • Standard wound care</td>
<td>Relevant outcomes include: • Disease-specific survival • Symptoms • Change in disease status • Morbid events • Quality of life</td>
</tr>
<tr>
<td>Individuals: • With lower-extremity ulcers due to venous insufficiency</td>
<td>Interventions of interest are: • Bioengineered skin substitutes other than Apligraf and Oasis Wound Matrix</td>
<td>Comparators of interest are: • Standard wound care</td>
<td>Relevant outcomes include: • Disease-specific survival • Symptoms • Change in disease status • Morbid events • Quality of life</td>
</tr>
<tr>
<td>Individuals: • With dystrophic epidermolysis bullosa</td>
<td>Interventions of interest are: • Bioengineered skin substitutes (ie, OrCel)</td>
<td>Comparators of interest are: • Standard wound care</td>
<td>Relevant outcomes include: • Symptoms • Change in disease status • Morbid events • Quality of life</td>
</tr>
<tr>
<td>Individuals: • With deep dermal burns</td>
<td>Interventions of interest are: • Bioengineered skin substitutes (ie, Epigel, Integra Dermal Regeneration Template)</td>
<td>Comparators of interest are: • Standard wound care</td>
<td>Relevant outcomes include: • Disease-specific survival • Symptoms • Morbid events • Functional outcomes • Quality of life • Treatment-related morbidity</td>
</tr>
</tbody>
</table>

**DESCRIPTION**

Bioengineered skin and soft tissue substitutes may be derived from human tissue (autologous or allogeneic), nonhuman tissue (xenographic), synthetic materials, or a
composite of these materials. Bioengineered skin and soft tissue substitutes are being evaluated for a variety of conditions, including breast reconstruction and healing lower-extremity ulcers and severe burns. Acellular dermal matrix (ADM) products are also being evaluated for soft tissue repair.

**Objective**
The objective of this review is to determine whether the use of artificial skin and soft-tissue substitutes for reinforcement for surgical procedures, and healing of chronic wounds and burns improves the net health outcome.

**Background**

**Skin and Soft Tissue Substitutes**
Bioengineered skin and soft tissue substitutes may be either acellular or cellular. Acellular products (eg, dermis with cellular material removed) contain a matrix or scaffold composed of materials such as collagen, hyaluronic acid, and fibronectin. Acellular dermal matrix (ADM) products can differ in a number of ways, including as species source (human, bovine, porcine), tissue source (eg dermis, pericardium, intestinal mucosa), additives (eg antibiotics, surfactants), hydration (wet, freeze dried) and required preparation (multiple rinses, rehydration).

Cellular products contain living cells such as fibroblasts and keratinocytes within a matrix. The cells contained within the matrix may be autologous, allogeneic, or derived from other species (eg, bovine, porcine). Skin substitutes may also be composed of dermal cells, epidermal cells, or a combination of dermal and epidermal cells, and may provide growth factors to stimulate healing. Bioengineered skin substitutes can be used as either temporary or permanent wound coverings.

**Applications**
There are a large number of potential applications for artificial skin and soft tissue products. One large category is nonhealing wounds, which potentially encompasses diabetic neuropathic ulcers, vascular insufficiency ulcers, and pressure ulcers. A substantial minority of such wounds do not heal adequately with standard wound care, leading to prolonged morbidity and increased risk of mortality. For example, nonhealing lower-extremity wounds represent an ongoing risk for infection, sepsis, limb amputation and death. Bioengineered skin and soft tissue substitutes have the potential to improve rates of healing and reduce secondary complications.

Other situations in which bioengineered skin products might substitute for living skin grafts include certain postsurgical states (eg, breast reconstruction) in which skin coverage is inadequate for the procedure performed, or for surgical wounds in patients with compromised ability to heal. Second- and third-degree burns are another indication in which artificial skin products may substitute for auto- or allografts. Certain primary dermatologic conditions that involve large areas of skin breakdown (eg, bullous diseases) may also be conditions in which artificial skin products can be considered as substitutes.
for skin grafts. ADM products are also being evaluated in the repair of other soft tissues including rotator cuff repair, following oral and facial surgery, hernias, and other conditions.

**Regulatory Status**
A large number of artificial skin products are commercially available or in development. The following summary of commercially available skin substitutes describes those products that have substantial relevant evidence on efficacy.

**Acellular Dermal Matrix Products**
Allograft acellular dermal matrix (ADM) products derived from donated human skin tissue are supplied by tissue banks compliant with standards of the American Association of Tissue Banks (AATB) and U.S. Food and Drug Administration (FDA) guidelines. The processing removes the cellular components (ie, epidermis, all viable dermal cells) that can lead to rejection and infection. ADM products from human skin tissue are regarded as minimally processed and not significantly changed in structure from the natural material; FDA classifies ADM products as banked human tissue and therefore, does not require FDA approval.

- **AlloDerm®** (LifeCell Corp.) is an ADM (allograft) tissue-replacement product created from native human skin and processed so that the basement membrane and cellular matrix remain intact. Originally, AlloDerm® required refrigeration and rehydration before use. It is currently available in a ready-to-use product stored at room temperature. An injectable micronized form of AlloDerm® (Cymetra) is available.
- **Cortiva®** (previously marketed as AlloMax™ Surgical Graft and before that NeoForm™) is an acellular non-cross-linked human dermis allograft.
- **AlloPatch®** (Musculoskeletal Transplant Foundation) is an acellular human dermis allograft derived from the reticular layer of the dermis and marketed for wound care. This product is also marketed as FlexHD® for postmastectomy breast reconstruction.
- **FlexHD® and the newer formulation FlexHD® Pliable™** (Musculoskeletal Transplant Foundation) are acellular hydrated reticular dermis allograft derived from donated human skin.
- **DermACELL™** (LifeNet Health) is an allogeneic ADM processed with proprietary technologies MATRACELL® and PRESERVON®.
- **DermaMatrix** (Synthes) is a freeze-dried ADM derived from donated human skin tissue. DermaMatrix Acellular Dermis is processed by the Musculoskeletal Transplant Foundation.
- **DermaPure™** (Tissue Regenix Wound Care) is a single-layer decellularized human dermal allograft for the treatment of acute and chronic wounds.
- **GraftJacket® Regenerative Tissue Matrix** (also called GraftJacket Skin Substitute, KCI) is an acellular regenerative tissue matrix that has been processed from human skin supplied from U.S. tissue banks. The allograft is minimally processed to remove the epidermal and dermal cells, while preserving dermal structure. GraftJacket Xpress® is an injectable product.

FDA product code: FTM, OXF.
Biomatrix® (previously called MatriStem®) Wound Matrix, Multilayer Wound Matrix, Pelvic Floor Matrix, MicroMatrix, and Burn Matrix (all manufactured by ACell) are composed of porcine-derived urinary bladder matrix.

Hemicell (Encol) is an acellular collagen matrix from bovine dermis. In 2004, it was cleared for marketing by FDA through the 510(k) process for topical wound management that includes partial and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (e.g., abrasions, lacerations, second-degree burns, skin tears), and surgical wounds including donor sites/grafts.

Keramatrix® (Keraplast Research) is an open-cell foam comprised of freeze-dried keratin that is derived from acellular animal protein. In 2009, it was cleared for marketing by FDA through the 510(k) process under the name of Keratec. The wound dressings are indicated in the management of the following types of dry, light, and moderately exuding partial and full-thickness wounds: pressure (stage I-IV) and venous stasis ulcers, ulcers caused by mixed vascular etiologies, diabetic ulcers, donor sites, and grafts.

Kercos™ Omega3 Wound (Kercos) is an ADM derived from fish skin. It has a high content of omega 3 fatty acids and is intended for use in burn wounds, chronic wounds, and other applications.

Permacol™ (Covidien) is xenogenic and composed of cross-linked porcine dermal collagen. Cross-linking improves the tensile strength and long-term durability but decreases pliability.

PriMatrix™ (TEI Biosciences) is a xenogeneic ADM processed from fetal bovine dermis. It was cleared for marketing by FDA through the 510(k) process for partial- and full-thickness wounds; diabetic, pressure, and venous stasis ulcers; surgical wounds; and tunneling, draining, and traumatic wounds. FDA product code: KGN

SurgiMend® PRS (TEI Biosciences) is a xenogeneic ADM processed from fetal bovine dermis.

Strattice™ Reconstructive Tissue Matrix (LifeCell Corp) is a xenogenic non-cross-linked porcine-derived ADM. There are pliable and firm versions, which are stored at room temperature and come fully hydrated.

OASIS™ Wound Matrix (Cook Biotech) is a collagen scaffold (extracellular matrix) derived from porcine small intestinal submucosa. In 2000, it was cleared for marketing by FDA through the 510(k) process for the management of partial- and full-thickness wounds including pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled undermined wounds, surgical wounds, trauma wounds, and draining wounds. FDA Product code: KGN.

Living Cell Therapy

Apligraf® (Organogenesis) is a bilayered living cell therapy composed of an epidermal layer of living human keratinocytes and a dermal layer of living human fibroblasts. Apligraf® is supplied as needed, in 1 size, with a shelf-life of 10 days. In 1998, it was approved by FDA for use in conjunction with compression therapy for the treatment of noninfected, partial- and full-thickness skin ulcers due to venous...
insufficiency and in 2001 for full-thickness neuropathic diabetic lower-extremity ulcers nonresponsive to standard wound therapy. FDA product code: FTM

- Dermagraft® (Organogenesis) is composed of cryopreserved human-derived fibroblasts and collagen derived from newborn human foreskin and cultured on a bioabsorbable polyglactin mesh scaffold. Dermagraft has been approved by FDA for repair of diabetic foot ulcers. FDA product code: PFC

- TheraSkin® (Soluble Systems) is a cryopreserved split-thickness human skin allograft composed of living fibroblasts and keratinocytes and an extracellular matrix in epidermal and dermal layers. TheraSkin® is derived from human skin allograft supplied by tissue banks compliant with the American Association of Tissue Banks and FDA guidelines. It is considered a minimally processed human cell, tissue, and cellular- and tissue-based product by FDA.

- Epicel® (Genzyme Biosurgery) is an epithelial autograft composed of a patient’s own keratinocytes cultured ex vivo and is FDA-approved under a humanitarian device exemption (HDE) for the treatment of deep dermal or full-thickness burns comprising a total body surface area of 30% or more. It may be used in conjunction with split-thickness autografts or alone in patients for whom split-thickness autografts may not be an option due to the severity and extent of their burns. FDA product code: OCE

- OrCel™ (Forticell Bioscience; formerly Composite Cultured Skin) is an absorbable allogeneic bilayered cellular matrix, made of bovine collagen, in which human dermal cells have been cultured. It was approved by FDA premarket approval for healing donor site wounds in burn victims and under an HDE for use in patients with recessive dystrophic epidermolysis bullosa undergoing hand reconstruction surgery to close and heal wounds created by the surgery, including those at donor sites. FDA product code: ODS

**Biosynthetic Products**

- Biobrane®/Biobrane-L (Smith & Nephew) is a biosynthetic wound dressing constructed of a silicon film with a nylon fabric partially imbedded into the film. The fabric creates a complex 3-dimensional structure of trifilament thread, which chemically binds collagen. Blood/sera clot in the nylon matrix, adhering the dressing to the wound until epithelialization occurs. FDA product code: FRO

- Integra® Dermal Regeneration Template (also marketed as Omnigraft Dermal Regeneration Matrix, Integra LifeSciences) is a bovine, collagen/glycosaminoglycan dermal replacement covered by a silicone temporary epidermal substitute. It was approved by FDA for use in postexcisional treatment of life-threatening full-thickness or deep partial-thickness thermal injury where sufficient autograft is not available at the time of excision or not desirable because of the physiologic condition of the patient and for certain diabetic foot ulcers. Integra® Matrix Wound Dressing and Integra® Meshed Bilayer Wound Matrix are substantially equivalent skin substitutes and were cleared for marketing by FDA through the 510(k) process for other indications. Integra® Bilayer Wound Matrix (Integra LifeSciences) is designed to be used in conjunction with negative pressure wound therapy. The meshed bilayer provides a flexible wound covering and allows drainage of wound exudate. FDA product code: MDD
TransCyte™ (Advanced Tissue Sciences) consists of human dermal fibroblasts grown on nylon mesh, combined with a synthetic epidermal layer and was approved by FDA in 1997. TransCyte is intended as a temporary covering over burns until autografting is possible. It can also be used as a temporary covering for some burn wounds that heal without autografting.

**Synthetic Products**

Suprathel® (PolyMedics Innovations) is a synthetic copolymer membrane fabricated from a triopolymer of polylactide, trimethylene carbonate, and s-caprolactone. It is used to provide temporary coverage of superficial dermal burns and wounds. Suprathel® is covered with gauze and a dressing that is left in place until the wound has healed.

**POLICY**

**Note:** Use Q4100 for skin substitutes that do not have a unique code.

A. Breast reconstructive surgery:
   - when there is insufficient tissue expander or implant coverage by the pectoralis major muscle and additional coverage is required
   - when there is viable but compromised or thin postmastectomy skin flaps that are at risk of dehiscence or necrosis, or
   - the inframammary fold and lateral mammary folds have been undermined during mastectomy and reestablishment of these landmarks is needed using the following allogeneic acellular dermal matrix products may be considered medically necessary. (See Policy Guidelines)
     1. AlloDerm (Q4116)
     2. AlloMend
     3. Cortiva [AlloMax]
     4. DermACELL (Q4122)
     5. DermaMatrix
     6. FlexHD (Q4128)
     7. FlexHD Pliable
     8. GraftJacket (Q4107)

B. Treatment of chronic, noninfected, full-thickness diabetic lower-extremity ulcers using the following tissue-engineered skin substitutes may be considered medically necessary.
   1. AlloPatch a (Q4128)
   2. Apligraf b (Q4101)
   3. Dermagraft b (Q4106)
   4. Integra Omnipatch Dermal Regeneration Matrix (also known as Omnipatch) (Q4105)
   5. Integra Flowable Wound Matrix (Q4114)
C. Treatment of chronic, noninfected, partial- or full-thickness lower-extremity skin ulcers due to venous insufficiency, which have not adequately responded following a 1-month period of conventional ulcer therapy, using the following tissue-engineered skin substitutes may be considered **medically necessary**.
   1. Apligraf® (Q4101)
   2. Oasis Wound Matrix ™ (Q4102)

D. Treatment of dystrophic epidermolysis bullosa using the following tissue-engineered skin substitutes may be considered **medically necessary**.
   1. OrCel
      (for the treatment of mitten-hand deformity when standard wound therapy has failed and when provided in accordance with the humanitarian device exemption (HDE) specifications of the U.S. Food and Drug Administration [FDA])

E. Treatment of second- and third-degree burns using the following tissue-engineered skin substitutes may be considered **medically necessary**.
   1. Epigel
      (for the treatment of deep dermal or full-thickness burns comprising a total body surface area $\geq 30\%$ when provided in accordance with the HDE specifications of the FDA)
   2. Integra Dermal Regeneration Template™ (Q4105)

---

**Banked human tissue**
**FDA premarket approved**
**FDA 510(k) clearance**
**FDA-approved under an HDE**

F. All other uses of the bioengineered skin and soft tissue substitutes listed above are considered **experimental / investigational**.

G. All other skin and soft tissue substitutes not listed above are considered **experimental / investigational**, including, but not limited to:

<table>
<thead>
<tr>
<th>Experimental / Investigational</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. ACell UBM Hydrated / Lyophilized Wound Dressing</td>
</tr>
<tr>
<td>2. AlloSkin (Q4115)</td>
</tr>
<tr>
<td>3. AlloSkin AC, per sq cm (Q4141)</td>
</tr>
<tr>
<td>4. AlloSkin RT (Q4123)</td>
</tr>
<tr>
<td>5. Amino wound (Q4181)</td>
</tr>
<tr>
<td>6. Aongen Collagen Matrix</td>
</tr>
<tr>
<td>7. Architect ECM, PX, FX (Q4147)</td>
</tr>
<tr>
<td>8. ArthroFlex (Flex Graft) (Q4125)</td>
</tr>
<tr>
<td>9. Atlas Wound Matrix</td>
</tr>
<tr>
<td>10. Avagen Wound Dressing</td>
</tr>
<tr>
<td>11. AxoGuard Nerve Protector (AxoGen)</td>
</tr>
<tr>
<td>12.</td>
</tr>
<tr>
<td>13.</td>
</tr>
<tr>
<td>14.</td>
</tr>
<tr>
<td>15.</td>
</tr>
<tr>
<td>16.</td>
</tr>
<tr>
<td>17.</td>
</tr>
<tr>
<td>18.</td>
</tr>
<tr>
<td>19.</td>
</tr>
<tr>
<td>20.</td>
</tr>
<tr>
<td>21.</td>
</tr>
<tr>
<td>22.</td>
</tr>
<tr>
<td>23.</td>
</tr>
<tr>
<td>24.</td>
</tr>
<tr>
<td>25.</td>
</tr>
<tr>
<td>26.</td>
</tr>
<tr>
<td>27.</td>
</tr>
<tr>
<td>28.</td>
</tr>
<tr>
<td>29.</td>
</tr>
<tr>
<td>30.</td>
</tr>
<tr>
<td>31.</td>
</tr>
<tr>
<td>32.</td>
</tr>
<tr>
<td>33.</td>
</tr>
<tr>
<td>34.</td>
</tr>
<tr>
<td>35.</td>
</tr>
<tr>
<td>36.</td>
</tr>
<tr>
<td>37.</td>
</tr>
<tr>
<td>38.</td>
</tr>
<tr>
<td>39.</td>
</tr>
<tr>
<td>40.</td>
</tr>
<tr>
<td>41.</td>
</tr>
<tr>
<td>42.</td>
</tr>
<tr>
<td>43.</td>
</tr>
<tr>
<td>44.</td>
</tr>
<tr>
<td>45.</td>
</tr>
<tr>
<td>46.</td>
</tr>
<tr>
<td>47.</td>
</tr>
<tr>
<td>48.</td>
</tr>
<tr>
<td>49.</td>
</tr>
<tr>
<td>50.</td>
</tr>
<tr>
<td>51.</td>
</tr>
<tr>
<td>52.</td>
</tr>
<tr>
<td>53.</td>
</tr>
<tr>
<td>54.</td>
</tr>
<tr>
<td>55.</td>
</tr>
<tr>
<td>56.</td>
</tr>
<tr>
<td>57.</td>
</tr>
<tr>
<td>58.</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>59.</td>
</tr>
<tr>
<td>60.</td>
</tr>
<tr>
<td>61.</td>
</tr>
<tr>
<td>62.</td>
</tr>
<tr>
<td>63.</td>
</tr>
<tr>
<td>64.</td>
</tr>
<tr>
<td>65.</td>
</tr>
<tr>
<td>66.</td>
</tr>
<tr>
<td>67.</td>
</tr>
<tr>
<td>68.</td>
</tr>
<tr>
<td>69.</td>
</tr>
<tr>
<td>70.</td>
</tr>
<tr>
<td>71.</td>
</tr>
<tr>
<td>72.</td>
</tr>
<tr>
<td>73.</td>
</tr>
<tr>
<td>74.</td>
</tr>
<tr>
<td>75.</td>
</tr>
<tr>
<td>76.</td>
</tr>
<tr>
<td>77.</td>
</tr>
<tr>
<td>78.</td>
</tr>
<tr>
<td>79.</td>
</tr>
<tr>
<td>80.</td>
</tr>
<tr>
<td>81.</td>
</tr>
<tr>
<td>82.</td>
</tr>
<tr>
<td>83.</td>
</tr>
<tr>
<td>84.</td>
</tr>
<tr>
<td>85.</td>
</tr>
<tr>
<td>86.</td>
</tr>
<tr>
<td>87.</td>
</tr>
<tr>
<td>88.</td>
</tr>
<tr>
<td>89.</td>
</tr>
<tr>
<td>90.</td>
</tr>
<tr>
<td>91.</td>
</tr>
<tr>
<td>92.</td>
</tr>
<tr>
<td>93.</td>
</tr>
<tr>
<td>94.</td>
</tr>
<tr>
<td>95.</td>
</tr>
</tbody>
</table>

**Note:** Use Q4100 for skin substitutes that do not have a unique code.

**Policy Guidelines**
Clinical input has indicated that the various acellular dermal matrix (ADM) products used in breast reconstruction have similar efficacy. The products listed are those that have been identified for use in breast reconstruction. Additional ADM products may become available for this indication.
RATIONALE
This evidence review has been updated with searches of the MEDLINE database. The most recent literature update was performed through December 4, 2018.

The original review focused on the use of an allogeneic bioengineered skin substitutes in breast reconstructive surgery and was expanded in 2011 to address additional indications.

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are length of life, quality of life, and ability to function—including benefits and harms. Every clinical condition has specific outcomes that are important to patients and to managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of a technology, 2 domains are examined: the relevance and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

The primary end points of interest for trials of wound closure are as follows, consistent with guidance from the U.S. Food and Drug Administration for industry in developing products for treatment of chronic cutaneous ulcer and burn wounds:
1. Incidence of complete wound closure.
2. Time to complete wound closure (reflecting accelerated wound closure).
3. Incidence of complete wound closure following surgical wound closure.
4. Pain control.

The following is a summary of key literature to date.

Breast Reconstruction
A variety of breast reconstruction techniques are used postmastectomy, including implant-based (immediate or delayed following use of a tissue expander) and those using autologous tissue flaps. Some of these techniques have been used with acellular dermal matrix (ADM) to provide additional support or tissue coverage. The literature on ADM for breast reconstruction consists primarily of retrospective, uncontrolled series and systematic reviews of these studies.

A 2013 study used data from the American College of Surgeon’s National Surgical Quality Improvement Program to compare ADM-assisted tissue expander breast reconstruction (n=1717) to submuscular tissue expander breast reconstruction (n=7442) after mastectomy.¹ Complication rates did not differ significantly between the ADM-assisted (5.5%) and the submuscular tissue...
expander groups (5.3%; p=0.68). Rates of reconstruction-related complications, major complications, and 30-day reoperation did not differ significantly between cohorts.

**Systematic Reviews**
A 2016 meta-analysis by Lee and Mun included 23 studies (total N=6199 cases) on implant-based breast reconstruction that were published between February 2011 and December 2014.2 The analysis included an RCT and 3 prospective comparative cohort studies; the remainder was retrospective comparative cohort studies. Use of ADM did not affect the total complication rate (see Table 1). ADM significantly increased the risk of major infection, seroma, and flap necrosis, but reduced risks of capsular contracture and implant malposition. Use of ADM allowed for significantly greater intraoperative expansion (mean difference [MD], 79.63; 95% confidence interval [CI], 41.99 to 117.26; p<0.001) and percentage of intraoperative filling (MD=13.30; 95% CI, 9.95 to 16.65; p<0.001), and reduced the frequency of injections to complete expansion (MD = -1.56; 95% CI, -2.77 to -0.35; p=0.01).

<table>
<thead>
<tr>
<th>Outcome Measure</th>
<th>Relative Risk</th>
<th>95% Confidence Interval</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection</td>
<td>1.42</td>
<td>1.02 to 1.99</td>
<td>0.04</td>
</tr>
<tr>
<td>Seroma</td>
<td>1.41</td>
<td>1.12 to 1.78</td>
<td>0.004</td>
</tr>
<tr>
<td>Mastectomy flap necrosis</td>
<td>1.44</td>
<td>1.11 to 1.87</td>
<td>0.006</td>
</tr>
<tr>
<td>Unplanned return to the operating room</td>
<td>1.09</td>
<td>0.63 to 1.90</td>
<td>NS</td>
</tr>
<tr>
<td>Implant loss</td>
<td>1.00</td>
<td>0.68 to 1.48</td>
<td>NS</td>
</tr>
<tr>
<td>Total complications</td>
<td>1.08</td>
<td>0.87 to 1.34</td>
<td>NS</td>
</tr>
<tr>
<td>Capsular contracture</td>
<td>0.26</td>
<td>0.15 to 0.47</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Implant malposition</td>
<td>0.21</td>
<td>0.07 to 0.59</td>
<td>0.003</td>
</tr>
</tbody>
</table>

Adapted from Lee and Mun (2016).2 ADM: acellular dermal matrix; NS: not significant.

**AlloDerm**

**Randomized Controlled Trials**
In 2012, McCarthy et al reported on a multicenter, blinded RCT of AlloDerm in 2-stage expander/implant reconstruction.3 Seventy patients were randomized to AlloDerm ADM-assisted tissue expander/implant reconstruction or to submuscular tissue expander/implant placement. The trial was adequately powered to detect clinically significant differences in immediate postoperative pain but underpowered to detect the secondary end point of pain during tissue expansion. There were no significant differences between the groups in the primary outcomes of immediate postoperative pain (54.6 AlloDerm vs 42.8 controls on a 100-point visual analog scale) or pain during the expansion phase (17.0 AlloDerm vs 4.6 controls), or in the secondary outcome of rate of tissue expansion (91 days AlloDerm vs 108 days controls) and patient-reported physical well-being. There was no significant difference in adverse events, although the total number of adverse events was small.

**Comparisons Between Products**

**AlloDerm vs AlloMax**
Hinchcliffe et al (2017) conducted an RCT that compared AlloDerm with AlloMax (n=15 each) for implant-based breast reconstruction.4 Complications were assessed 7, 14, and 30 days postoperatively and biopsies of the ADMs were taken during implant exchange. Vessel density in the AlloMax biopsies was higher than in the AlloDerm biopsies. Complications were reported in 26.1% of AlloMax cases and 8.0% of AlloDerm cases; these complication rates did not differ statistically with the 30 patients in this trial.
**AlloDerm vs DermaMatrix**
Mendenhall et al (2017) conducted an RCT that compared AlloDerm with DermaMatrix in 111 patients (173 breasts). The there were no significant differences in overall rates of complications (AlloDerm, 15.4%; DermaMatrix, 18.3%; p=0.8) or implant loss (AlloDerm, 2.2%; DermaMatrix, 3.7%; p=0.5) between the 2 ADMs.

**AlloDerm vs FlexHD**
A 2014 retrospective review by Liu et al compared complication rates following breast reconstruction with AlloDerm or FlexHD in 382 consecutive women (547 breasts). Eighty-one percent of the sample was immediate reconstruction: 165 used AlloDerm and 97 used FlexHD. Mean follow-up was 6.4 months. Compared with breast reconstruction without the use of AlloDerm or FlexHD, ADM had a higher rate of delayed healing (20.2% vs 10.3%), although this finding might have been related to differences in fill volumes. In univariate analysis, there were no significant differences in complications (return to operating room, surgical site infection, seroma, hematoma, delayed healing, implant loss) between AlloDerm and FlexHD. In multivariate analysis, there were no significant differences between AlloDerm and FlexHD for the return to the operating room, surgical site infection, seroma, or delayed healing. Independent risk factors for implant loss included the use of FlexHD, single-stage reconstruction, and smoking.

**AlloDerm vs FlexHD Pliable and DermACELL**
Chang and Liu (2017) reported on a prospective comparison of FlexHD Pliable (32 breasts), AlloDerm (22 breasts), and DermACELL (20 breasts) in breast reconstruction. The choice of ADM was based on different years when each ADM was available for use at the investigators’ institution; patient demographics were comparable between groups. The pieces of ADM used were all the same size (8 × 16 cm) to eliminate an effect of size on outcomes. The time to drain removal was longer with AlloDerm (26 days) than with FlexHD (20 days) and DermACELL (15 days; p=0.001). Complications were low (4 in the Flex Pliable group, 2 in the AlloDerm group, 1 in the DermACELL group), with no significant differences between groups. At the time of exchange for a permanent implant or free flap reconstruction, all grafts had completely incorporated into the mastectomy skin flaps. No patients developed complications requiring removal of the ADM.

Pittman et al (2017) reported a retrospective pilot study of the use of AlloDerm (50 breasts) and DermACELL (50 breasts). The choice of ADM was based on products available during different years and patient demographics were similar between the 2 groups. Patients in the DermACELL group had a significantly lower incidence of “red breast syndrome” (0% vs 26%, p=0.001) and fewer days until drain removal (15.8 days vs 20.6 days, p=0.017). There were no significant differences in the rates of other complications.

**Strattice**
Dikmans et al (2017) reported on early safety outcomes from an open-label multicenter RCT that compared porcine ADM-assisted 1-stage expansion with 2-stage implant-based breast reconstruction (see Table 2). One-stage breast reconstruction with porcine ADM was associated with a higher risk of surgical complications, reoperation, and with removal of implant, ADM, or both (see Table 3). The trial was stopped early due to safety concerns, but it cannot be determined from this study design whether the increase in complications was due to the use of the xenogenic ADM or to the comparison between 1-stage and 2-stage reconstruction.
Table 2. Summary of Key RCT Characteristics

<table>
<thead>
<tr>
<th>Author</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dikmans et al (2017)</td>
<td>EU</td>
<td>8</td>
<td>2013-2015</td>
<td>Women intending to undergo skin-sparing mastectomy and immediate IBBR</td>
<td>59 patients (91 breasts) undergoing 1-stage IBBR with ADM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>62 women (92 breasts) undergoing 2-stage IBBR</td>
</tr>
</tbody>
</table>

ADM: acellular dermal matrix; IBBR: implant-based breast reconstruction; RCT: randomized controlled trial.

Table 3. Summary of Key RCT Outcomes

<table>
<thead>
<tr>
<th>Study</th>
<th>Surgical Complications</th>
<th>Severe Adverse Events</th>
<th>Reoperation</th>
<th>Removal of Implant, ADM, or Both</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dikmans et al (2017)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-stage with ADM, n (%)</td>
<td>27 (46)</td>
<td>26 (29)</td>
<td>22 (37)</td>
<td>24 (26)</td>
</tr>
<tr>
<td>2-stage with ADM, n (%)</td>
<td>11 (18)</td>
<td>5 (5)</td>
<td>9 (15)</td>
<td>4 (5)</td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>3.81 (2.67 to 5.43)</td>
<td>3.38 (2.10 to 5.45)</td>
<td>8.80 (8.24 to 9.40)</td>
<td></td>
</tr>
<tr>
<td>p</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

ADM: acellular dermal matrix; CI: confidence interval; OR: odds ratio; RCT: randomized controlled trial.

Section Summary: Breast Reconstruction
Results of a systematic review found no difference in overall complication rates between ADM allograft and standard procedures for breast reconstruction. Although reconstructions with ADM have been reported to have higher seroma, infection, and necrosis rates than reconstructions without ADM, rates of capsular contracture and malposition of implants may be reduced. Thus, in cases where there is limited tissue coverage, the available studies may be considered sufficient to permit informed decision-making about risks and benefits of using allogeneic ADM for breast reconstruction.

Tendon Repair
Graftjacket
In 2012, Barber et al reported an industry-sponsored multicenter RCT of augmentation with Graftjacket human ADM for arthroscopic repair of large (>3 cm) rotator cuff tears involving 2 tendons. Twenty-two patients were randomized to Graftjacket augmentation and 20 patients to no augmentation. At a mean follow-up of 24 months (range, 12-38 months), the American Shoulder and Elbow Surgeons score improved from 48.5 to 98.9 in the Graftjacket group and from 46.0 to 94.8 in the control group (p=0.035). The Constant score improved from 41 to 91.9 in the Graftjacket group and from 45.8 to 85.3 in the control group (p=0.008). The University of California, Los Angeles score did not differ significantly between groups. Gadolinium-enhanced magnetic resonance imaging (MRI) scans showed intact cuffs in 85% of repairs in the Graftjacket group and 40% of repairs in the control group. However, no correlation was found between MRI findings and clinical outcomes. Rotator cuff retears occurred in 3 (14%) patients in the Graftjacket group and 9 (45%) patients in the control group.

Section Summary: Tendon Repair
One small RCT was identified that found improved outcomes with Graftjacket ADM allograft for rotator cuff repair. Although results of this trial were promising, additional study with a larger number of patients is needed to evaluate consistency of findings and determine the effects of this technology with greater certainty.
Surgical Repair of Hernias or Parastomal Reinforcement
A 2013 systematic review evaluated the clinical effectiveness of acellular collagen-based scaffolds for the repair of incisional hernias.\(^{11}\) The bioprosthesis materials could be harvested from bovine pericardium, human cadaveric dermis, porcine small intestine mucosa, porcine dermal collagen, or bovine dermal collagen. Products included in the search were Surgisis, Tutomesh, Veritas, AlloDerm, FlexHD, AlloMax, CollaMend, Permacol, Strattice, FortaGen, ACell, DermaMatrix, XenMatrix, and SurgiMend. Sixty publications with 1212 repairs were identified and included in the review, although meta-analysis could not be performed. There were 4 level III studies (2 AlloDerm, 2 Permacol); the remainder was level IV or V. The largest number of publications were on AlloDerm (n=27) and Permacol (n=18). No publications on incisional hernia repair were identified for AlloMax, FortaGen, DermaMatrix, or ACell. The overall incidence of a surgical site occurrence (eg, postoperative infection, seroma/hematoma, pain, bulging, dehiscence, fistula, mechanical failure) was 82.6% for porcine small intestine mucosa, 50.7% for xenogenic dermis, 48.3% for human dermis, and 6.3% for xenogenic pericardium. No comparative data were identified that could establish superiority to permanent synthetic meshes.

AlloDerm as an Overlay
In 2007, Espinosa-de-los-Monteros et al retrospectively reviewed 39 abdominal wall reconstructions with AlloDerm performed in 37 patients and compared them with 39 randomly selected cases.\(^ {12}\) They reported a significant decrease in recurrence rates when human cadaveric acellular dermis was added as an overlay to primary closure plus rectus muscle advancement and imbrication in patients with medium-sized hernias. However, no differences were observed when adding human cadaveric acellular dermis as an overlay to patients with large-size hernias treated with underlay mesh.

Comparisons Between Products
AlloDerm vs Surgisis Gold
Gupta et al (2006) compared the efficacy and complications associated with use of AlloDerm and Surgisis bioactive mesh in 74 patients who underwent ventral hernia repair.\(^ {13}\) The first 41 procedures were performed using Surgisis Gold 8-ply mesh formed from porcine small intestine submucosa, and the remaining 33 patients had ventral hernia repair with AlloDerm. Patients were seen 7 to 10 days after discharge from the hospital and at 6 weeks. Any signs of wound infection, diastasis, hernia recurrence, changes in bowel habits, and seroma formation were evaluated. The use of the AlloDerm mesh resulted in 8 (24%) hernia recurrences. Fifteen (45%) of the AlloDerm patients developed a diastasis or bulging at the repair site. Seroma formation was only a problem in 2 patients.

AlloDerm vs FlexHD
A 2013 study compared AlloDerm with FlexHD for complicated hernia surgery.\(^ {14}\) From 2005 to 2007, AlloDerm was used to repair large (>200 cm\(^2\)) symptomatic complicated ventral hernias that resulted from trauma or emergency surgery (n=55). From 2008 to 2010, FlexHD was used to repair large, complicated ventral hernias in patients meeting the same criteria (n=40). The 2 groups were comparable at baseline. At 1 year follow-up, all AlloDerm patients were diagnosed with hernia recurrence (abdominal laxity, functional recurrence, true recurrence) requiring a second repair. Eleven (31%) patients in the FlexHD group required a second repair. This comparative study is limited by the use of nonconcurrent comparisons, which is prone to selection bias and does not control for temporal trends in outcomes.
FlexHD vs Strattice
Roth et al (2017) reported on a prospective study assessing clinical and quality of life outcomes following complex hernia repair with a human (FlexHD) or porcine (Strattice) ADM. The study was funded by the Musculoskeletal Transplant Foundation, which prepares and supplies FlexHD. Patients were enrolled if they had a hernia at least 6 cm in the transverse dimension, active or prior infection of the abdominal wall, and/or enterocutaneous fistula requiring mesh removal. Eighteen (51%) of the 35 patients had undergone a previous hernia repair. After abdominal wall repair with the ADM, 20 (57%) patients had a surgical site occurrence, and nearly one-third had hospital readmission. The type of biologic material did not impact hernia outcomes. There was no comparison with synthetic mesh in this study, limiting interpretation.

Strattice vs Synthetic Mesh
In 2014, Bellows et al reported early results of an industry-sponsored multicenter RCT that compared Strattice (non-cross-linked porcine ADM, n=84) with a standard synthetic mesh (n=88) for the repair of inguinal hernias. The trial was designed by the surgeons and was patient- and assessor-blinded to reduce risk of bias. Blinding continued through 2 years of follow-up. The primary outcome was resumption of activities of daily living at 1 year. Secondary outcomes included complications, recurrences, or chronic pain (ie, pain that did not disappear by 3 months postsurgery). At 3-month follow-up, there were no significant differences in either the occurrence or type of wound events (relative risk, 0.98; 95% CI, 0.52 to 1.86). Pain was reduced from 1 to 3 days postoperative in the group treated with Strattice, but at 3 month follow-up pain scores did not differ significantly between groups.

Strattice vs No Reinforcement
Also in 2014, the PRISM Study Group reported a multicenter, double-blinded, randomized trial of Strattice for parastomal reinforcement in patients undergoing surgery for permanent abdominal wall ostomies. Patients were randomized to standard stoma construction with no reinforcement (n=58) or stoma construction with Strattice as parastomal reinforcement (n=55). At 24-month follow-up (n=75), the incidence of parastomal hernias was similar for the 2 groups (13.2% of controls, 12.2% of study group).

Section Summary: Surgical Repair of Hernias or Parastomal Reinforcement
Current evidence does not support a benefit of ADMs in hernia repair or prevention of parastomal hernia. Additional RCTs are needed to compare biologic mesh with synthetic mesh and to determine if there is a patient population that would benefit from these products.

Diabetic Lower-Extremity Ulcers Systematic Reviews
A 2016 Cochrane review evaluated skin substitutes for the treatment of diabetic foot ulcers. Seventeen trials (total N=1655 participants) were included in the meta-analysis. Most trials identified were industry-sponsored, and an asymmetric funnel plot indicated publication bias. Pooled results of published trials found that skin substitutes increased the likelihood of achieving complete ulcer closure compared with standard of care (SOC) alone (relative risk, 1.55; 95% CI, 1.30 to 1.85). Use of skin substitutes also led to a statistically significant reduction in amputations (relative risk, 0.43; 95% CI, 0.23 to 0.81), although the absolute risk difference was small. Analysis by individual products found a statistically significant benefit on ulcer closure for Apligraf, EpiFix, and Hyalograft-3D. The products that did not show a statistically significant benefit for ulcer closure were Dermagraft, Graftjacket, Kaloderm, and OrCel. Individual RCTs are described next.
Martinson and Martinson (2016) conducted an industry-sponsored analysis of Medicare claims data (13,193 treatment episodes) to compare efficacy and cost of skin substitutes for the management of diabetic foot ulcers. Included in the analysis were treatment episodes with Apligraf (37%), Dermagraft (42%), Oasis (19%), and Cytal (MatriStem, 2%). The mean number of applications was 3.24 for Apligraf, 4.48 for Oasis, 5.53 for Cytal, and 5.96 for Dermagraft. All comparisons were statistically significant. Healing at 90 days was modestly but statistically higher for Oasis (63%) and Cytal (62%) than for Apligraf (58%) or Dermagraft (58%). Amputation rates were similar after treatment with the 4 products, ranging from 1.3% for Oasis to 2.1% for Cytal. Guo et al (2017) reported a systematic review of ADM for the treatment diabetic foot ulcer. Most data were from an RCT of Integra Dermal Regeneration Template, which is a bilayer product with the outer layer composed of a thin silicone film and not a pure ADM.

**Apligraf, Dermagraft, AlloPatch, Integra Dermal Regeneration Template, or Integra Flowable Wound Matrix**

**Apligraf**
Veves et al (2001) reported on a randomized prospective trial on the effectiveness of Apligraf (previously called Graftskin), a living skin equivalent, in treating noninfected nonischemic chronic plantar diabetic foot ulcers. The trial involved 24 centers in the United States; 208 patients were randomized to ulcer treatment with Apligraf (112 patients) or saline-moistened gauze (96 patients, control group). Standard state-of-the-art adjunctive therapy, including extensive surgical débridement and adequate foot off-loading, was provided in both groups. Apligraf was applied at the beginning of the study and weekly thereafter for a maximum of 4 weeks (maximum of 5 applications) or earlier if complete healing occurred. At the 12-week follow-up visit, 63 (56%) Apligraf-treated patients achieved complete wound healing compared with 36 (38%) in the control group (p=0.004). The Kaplan-Meier method median time to complete closure was 65 days for Apligraf, significantly lower than the 90 days observed in the control group (p=0.003). The rates of adverse reactions were similar between groups, except osteomyelitis and lower-limb amputations, both of which were less frequent in the Apligraf group. Trialists concluded that application of Apligraf for a maximum of 4 weeks resulted in higher healing rates than state-of-the-art treatment and was not associated with any significant adverse events. This trial was reviewed in a 2001 TEC Assessment, which concluded that Apligraf, in conjunction with good local wound care, met the TEC criteria for the treatment of diabetic ulcers that fail to respond to conservative management.

Steinberg et al (2010) reported on a study of 72 subjects from Europe and Australia that assessed the safety and efficacy of Apligraf in the treatment of noninfected diabetic foot ulcers. Study design and patient population were similar to the 208-subject U.S. study (previously described), which led to Food and Drug Administration (FDA) approval of Apligraf for the treatment of diabetic foot ulcers. For these studies, subjects with noninfected neuropathic diabetic foot ulcers present for at least 2 weeks were enrolled in prospective, multicenter, open-label RCTs that compared Apligraf use plus standard therapy (sharp débridement, standard wound care, off-loading) with standard therapy alone. Pooling of data was performed because of the similarity and consistency of the 2 studies. Efficacy and safety results were consistent across studies independent of mean ulcer duration, which was significantly longer in the European study (21 months vs10 months in the U.S. study). Reported adverse events by 12 weeks were comparable across treatment groups in the 2 studies. Efficacy measures demonstrated superiority of Apligraf treatment over control-treated groups in both studies. Combining the data from both studies, 55.2% (80/145) of Apligraf subjects had complete wound closure by 12 weeks.
compared with 34.3% (46/134) of control subjects (p<0.001), and Apligraf subjects had a significantly shorter time to complete wound closure (p<0.001). The authors concluded that both the EU and U.S. studies exhibited superior efficacy and comparable safety for subjects treated with Apligraf compared with control subjects and that the studies provided evidence of the benefit of Apligraf in treating diabetic foot ulcer.

In 2010, Kirsner et al analyzed 2517 patients with diabetic neuropathic foot ulcers treated between 2001 and 2004.24 This retrospective analysis used a wound care database; the patients received advanced biologic therapy, specifically, Apligraf (446 patients), Regranex, or Procuren. The analysis found that advanced biologic therapy was used, on average, within 28 days from the first wound clinic visit and was associated with a median time to healing of 100 days. Wounds treated with engineered skin (Apligraf) as the first advanced biologic therapy were 31% more likely to heal than wounds first treated with topical recombinant growth factor (p<0.001) and 40% more likely to heal than those first treated with platelet releasate (p=0.01). Wound size, wound grade, duration of wound, and time to initiation of advanced biologic therapy affected the time to healing.

**Dermagraft**

A 2003 pivotal multicenter FDA-regulated trial randomized 314 patients with chronic diabetic ulcers to Dermagraft (human-derived fibroblasts cultured on mesh) or control.25 Over the 12-week study, patients received up to 8 applications of Dermagraft. All patients received pressure-reducing footwear and were encouraged to stay off their study foot as much as possible. At 12 weeks, the median percent wound closure for the Dermagraft group was 91% compared with 78% for the control group. Ulcers treated with Dermagraft closed significantly faster than ulcers treated with conventional therapy. No serious adverse events were attributed to Dermagraft. Ulcer infections developed in 10.4% of the Dermagraft patients compared with 17.9% of the control patients. Together, there was a lower rate of infection, cellulitis, and osteomyelitis in the Dermagraft-treated group (19% vs 32.5%). A 2015 retrospective analysis of the trial data found a significant reduction in amputation/bone resection rates with Dermagraft (5.5% vs 12.6%, p=0.031).26 Of the 28 cases of amputation/bone resection, 27 were preceded by ulcer-related infection.

**AlloPatch**

AlloPatch Pliable human reticular acellular dermis was compared with SOC in an industry-sponsored multicenter trial by Zelen et al (2017, 2018).27,28 The initial trial with 20 patients per group was extended to determine the percent healing at 6 weeks with 40 patients per group. Healing was evaluated by the site investigator and confirmed by an independent panel. At 6 weeks, 68% (27/40) of wounds treated using AlloPatch had healed compared with 15% (6/40) in the SOC-alone group (p<0.001). At 12 weeks, 80% (32/40) of patients in the AlloPatch group had healed compared to 30% (12/40) in the control group. Mean time to heal within 12 weeks was 38 days (95% CI: 29-47 days) for the HR-ADM group and 72 days (95% CI: 66-78 days) for the SOC group (p < 0.001).

**Integra Omnigraft Dermal Regeneration Template or Integra Flowable Wound Matrix**

Integra Dermal Regeneration Template is a biosynthetic skin substitute that is FDA-approved for life-threatening thermal injury. The FOUNDER (Foot Ulcer New Dermal Replacement) multicenter study (32 sites) assessed Integra Dermal Regeneration Template (marketed as Omnigraft) for chronic nonhealing diabetic foot ulcers under an FDA-regulated investigational device exemption.29 A total of 307 patients with at least 1 chronic diabetic foot ulcer were randomized.
to treatment with the Integra Template or a control condition (sodium chloride gel 0.9%). Treatment was given for 16 weeks or until wound closure. There was a modest increase in wound closure with the Integra Template (51% vs 32%, p=0.001) and a shorter median time to closure (43 days vs 78 days, p=0.001). There was a strong correlation between investigator-assessed and computerized planimetry assessment of wound healing (r=0.97). Kaplan-Meier analysis showed the greatest difference between groups in wound closure up to 10 weeks, with diminishing differences after 10 weeks. Trial strengths included adequate power to detect an increase in wound healing of 18%, which was considered to be clinically significant, secondary outcomes of wound closure and time to wound closure by computerized planimetry, and ITT analysis.

Integra Flowable Wound Matrix is composed of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan. It is supplied as a granular product that is mixed with saline. Campitiello et al (2017) published an RCT that compared the flowable matrix with wet dressing in 46 patients who had Wagner grade 3 diabetic foot ulcers. The ulcers had developed over 39 weeks. Complete healing at 6 weeks was achieved in significantly more patients in the Integra Flowable Wound Matrix group than in the control group, while the risk of rehospitalization and major amputation was reduced with Integra Flowable Wound Matrix (see Table 4).

Table 4. Probability of Wound Healing With IFWM vs SOC

<table>
<thead>
<tr>
<th>Study</th>
<th>Complete Wound Healing</th>
<th>Rehospitalization</th>
<th>Major Amputation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Campitiello et al (2017)</td>
<td>20 (86.95)</td>
<td>2 (6.69)</td>
<td>1 (4.34)</td>
</tr>
<tr>
<td>IFWM, n (%)</td>
<td>12 (52.17)</td>
<td>10 (43.47)</td>
<td>7 (30.43)</td>
</tr>
<tr>
<td>RR (95% CI)</td>
<td>1.67 (1.09 to 2.54)</td>
<td>0.10 (0.01 to 0.72)</td>
<td>0.16 (0.02 to 1.17)</td>
</tr>
<tr>
<td>p</td>
<td>0.010</td>
<td>0.001</td>
<td>0.028</td>
</tr>
</tbody>
</table>

CI: confidence interval; IFWM: Integra Flowable Wound Matrix; RR: relative risk; SOC: standard of care.

Section Summary: Apligraf, Dermagraft, AlloPatch, or Integra for Diabetic Lower-Extremity Ulcers

RCTs have demonstrated the efficacy of Apligraf, Dermagraft, AlloPatch, Integra Dermal Regeneration Template, and Integra Flowable Wound Matrix over SOC for the treatment of diabetic lower-extremity ulcers.

Bioengineered Skin Substitutes Other Than Apligraf, Dermagraft, AlloPatch, or Integra Graftjacket Regenerative Tissue Matrix

Brigido et al (2004) reported a small (N=40) randomized pilot study comparing Graftjacket with conventional treatment for chronic nonhealing diabetic foot ulcers. Control patients received conventional therapy with débridement, wound gel with gauze dressing, and off-loading. Graftjacket patients received surgical application of the scaffold using skin staples or sutures and moistened compressive dressing. A second graft application was necessary after the initial application for all patients in the Graftjacket group. Preliminary one month results showed that, after a single treatment, ulcers treated with Graftjacket healed at a faster rate than conventional treatment. There were significantly greater decreases in wound length (51% vs 15%), width (50% vs 23%), area (73% vs 34%), and depth (89% vs 25%), respectively. With follow-up to four weeks, no data were reported on the proportion with complete closure or the mean time to heal. All grafts were incorporated into the host tissue.

Reyzelman et al (2009) reported an industry-sponsored multicenter randomized study that compared a single application of Graftjacket with SOC in 86 patients with diabetic foot ulcers.
Eight patients, six in the study group and two in the control group, did not complete the trial. At 12 weeks, complete healing was observed in 69.6% of the Graftjacket group and 46.2% of controls. After adjusting for ulcer size at presentation, a statistically significant difference in nonhealing rate was calculated, with odds of healing 2.0 times higher in the study group. Mean healing time was 5.7 weeks for the Graftjacket group vs 6.8 weeks for the control group. The authors did not report whether this difference was statistically significant. Median time to healing was 4.5 weeks for Graftjacket (range, 1-12 weeks) and 7.0 weeks for control (range, 2-12 weeks). Kaplan-Meier method survivorship analysis for time to complete healing at 12 weeks showed a significantly lower nonhealing rate for the study group (30.4%) than for the control group (53.9%). The authors commented that a single application of Graftjacket, as used in this study, was often sufficient for complete healing. Conclusions drawn from this study are limited by the small study population and differences in ulcer size at baseline. Questions also remain whether the difference in mean time to healing is statistically or clinically significant.

In 2015, Reyzelman and Bazarov\textsuperscript{33} reported an industry-sponsored meta-analysis of Graftjacket for diabetic foot ulcers that included the 2 studies described above and a third RCT by Brigido (2006)\textsuperscript{34} with 28 patients (total N=154 patients). The time to heal was estimated for the 2004 Brigido study, based on the average wound reduction per week. The estimated difference in time to heal was considerably larger for Brigido’s 2004 study (-4.30 weeks) than for the other 2 studies that measured the difference in time to heal (-1.58 and -1.10 weeks). Analysis of the proportion of wounds that healed included Brigido (2006) and Reyzelman et al (2009). The odds ratio in the smaller study by Brigido was considerably larger, with a lack of precision in the estimate (odds ratio, 15.0; 95% CI, 2.26 to 99.64), and the combined odds (3.75; 95% CI, 1.72 to 8.19) was not significant when analyzed using a random-effects model. Potential sources of bias, noted by Reyzelman and Bazarov, included publication and reporting biases, study selection biases, incomplete data selection, post hoc manipulation of data, and subjective choice of analytic methods. Overall, results of these studies do not provide convincing evidence that Graftjacket is more effective than SOC for healing diabetic foot ulcers.

**DermACELL vs Graftjacket Regenerative Tissue Matrix or SOC**

DermACELL and Graftjacket are both composed of human ADM. In 2016, Walters et al reported on a multicenter randomized comparison of DermACELL, Graftjacket, or SOC (2:1:2 ratio) in 168 patients with diabetic foot ulcers.\textsuperscript{35} The study was sponsored by LifeNet Health, a nonprofit organ procurement association and processor for DermACELL. At 16 weeks, the proportion of completely healed ulcers was 67.9% for DermACELL, 47.8% for Graftjacket, and 48.1% for SOC. The 20% difference in completely healed ulcers was statistically significant for DermACELL vs SOC (p=0.039). The mean time to complete wound closure did not differ significantly for DermACELL (8.6 weeks), Graftjacket (8.6 weeks), and SOC (8.7 weeks).

A second report from this study was published in 2017.\textsuperscript{36} This analysis compared DermACELL with SOC and did not include the Graftjacket arm. The authors reported that either 1 or 2 applications DermACELL led to a greater proportion of wounds healed compared with SOC in per protocol analysis (see Table 5), but there was no significant difference between DermACELL (1 or 2 applications) and SOC when analyzed by intention-to-treat. For the group of patients who received only a single application, the percentage of patients who achieved complete wound healing was significantly higher than SOC at 16 and 24 weeks, but not at 12 weeks. Although reported as ITT analysis, results were analyzed only for the group who received a single application of DermACELL. This would not typically be considered ITT unless the number of DermACELL applications was prespecified.
Table 5. Probability of Wound Healing in Per Protocol Analysis of DermACEILL vs SOC

<table>
<thead>
<tr>
<th>Study</th>
<th>% With Wound Healing at 12 Wk</th>
<th>% With Wound Healing at 16 Wk</th>
<th>% With Wound Healing at 24 Wk</th>
<th>% With Wound Healing at 12 Wk</th>
<th>% With Wound Healing at 16 Wk</th>
<th>% With Wound Healing at 24 Wk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cazzell et al (2017)</td>
<td>65.0%</td>
<td>82.5%</td>
<td>89.7%</td>
<td>NR</td>
<td>67.9%</td>
<td>83.7%</td>
</tr>
<tr>
<td>DermACEILL, %</td>
<td>41.1%</td>
<td>48.1%</td>
<td>67.3%</td>
<td>NR</td>
<td>48.1%</td>
<td>67.3%</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>1.97</td>
<td>2.40</td>
<td>2.11</td>
<td>1.72</td>
<td>1.04 to 2.83</td>
<td>1.55</td>
</tr>
<tr>
<td></td>
<td>(1.1 to 3.5)</td>
<td>(1.4 to 4.1)</td>
<td>(1.3 to 3.5)</td>
<td>(1.04 to 2.83)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p</td>
<td>0.012</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>NS</td>
<td>0.028</td>
<td>0.049</td>
</tr>
</tbody>
</table>

CI: confidence interval; HR: hazard ratio; NR: not reported; NS: not significant; SOC: standard of care.

**TheraSkin vs Dermagraft**

Sanders et al (2014) reported on a small (N=23) industry-funded randomized comparison of TheraSkin (cryopreserved human skin allograft with living fibroblasts and keratinocytes) and Dermagraft for diabetic foot ulcers. Wound size at baseline ranged from 0.5 to 18.02 cm²; the average wound size was about 5 cm² and was similar for the 2 groups (p=0.51). Grafts were applied according to manufacturers’ instructions over the first 12 weeks of the study until healing, with an average of 4.4 TheraSkin grafts (every 2 weeks) compared with 8.9 Dermagraft applications (every week). At week 12, complete wound healing was observed in 63.6% of ulcers treated with TheraSkin and 33.3% of ulcers treated with Dermagraft (p<0.049). At 20 weeks, complete wound healing was observed in 90.9% of the TheraSkin-treated ulcers compared with 66.7% of the Dermagraft group (p=0.428).

**TheraSkin vs Apligraf**

DiDomenico et al (2011) compared TheraSkin with Apligraf for the treatment of diabetic foot ulcers in a small (N=29) RCT. The risk of bias in this study is uncertain, because reporting did not include a description of power analysis, statistical analysis, method of randomization, or blinding. The percentage of wounds closed at 12 weeks was 41.3% in the Apligraf group and 66.7% in the TheraSkin group. Results at 20 weeks were not substantially changed from those at 12 weeks, with 47.1% of wounds closed in the Apligraf group and 66.7% closed in the TheraSkin group. The percentage healed in the Apligraf group was lower than expected based on prior studies. The average number of grafts applied was similar for both groups (1.53 for Apligraf, 1.38 for TheraSkin). The low number of dressing changes may have influenced results, with little change in the percentage of wounds closed between 12 and 20 weeks. An adequately powered trial with blinded evaluation of wound healing and a standard treatment regimen would permit greater certainty on the efficacy of this product.

**Cytal (MatriStem) vs Dermagraft**

Frykberg et al (2017) reported a prespecified interim analysis of an industry-funded multicenter noninferiority trial of Cytal (a porcine urinary bladder–derived extracellular matrix) vs Dermagraft in 56 patients with diabetic foot ulcers. The mean duration of ulcers before treatment was 263 days (range, 30-1095 days). The primary outcome was the percent wound closure with up to 8 weeks of treatment using blinded evaluation of photographs. Intention-to-treat (ITT) analysis found complete wound closure in 5 (18.5%) wounds treated with Cytal compared with 2 (6.9%) wounds treated with Dermagraft (p=NS). Quality of life, measured by the Diabetic Foot Ulcer Scale, improved from 181.56 to 151.11 in the Cytal group and from 184.46 to 195.73 in the Dermagraft group (p=0.074). It should be noted that this scale is a subjective measure and...
patients were not blinded to treatment. Power analysis indicated that 92 patients would be required; further recruitment is ongoing for completion of the study.

**PriMatrix**
Kavros et al (2014) reported a prospective multicenter study of PriMatrix (a xenograft fetal bovine dermal collagen matrix) for the treatment of chronic diabetic foot ulcers in 55 patients.\(^{40}\) Average duration of ulcers before treatment was 286 days, and average wound area was 4.34 cm\(^2\). Of the 46 patients who completed the study, 76% healed by 12 weeks with an average of 2 applications of PriMatrix. For the ITT population, 64% of wounds healed by 12 weeks.

Karr (2011) published a retrospective comparison of PriMatrix and Apligraf in 40 diabetic foot ulcers.\(^{41}\) The first 20 diabetic foot ulcers matching the inclusion and exclusion criteria for each graft were compared. The criteria were: diabetic foot ulcers of 4 weeks in duration; ulcer of at least 1 cm\(^2\) in diameter and to the depth of subcutaneous tissue; healthy tissue at the ulcer; adequate arterial perfusion to heal; and ability to off-load the diabetic ulcer. The time to complete healing for PriMatrix was 38 days with 1.5 applications compared with 87 days with 2 applications for Apligraf. Although promising, additional study with a larger number of subjects is needed to compare the efficacy of PriMatrix with current SOC or advanced wound therapies.

**Oasis Wound Matrix vs Regranex Gel**
Niezgoda et al (2005) compared healing rates at 12 weeks for full-thickness diabetic foot ulcers treated with OASIS Wound Matrix (a porcine acellular wound care product) to Regranex Gel.\(^{42}\) This industry-sponsored, multicenter RCT was conducted at 9 outpatient wound care clinics and involved 73 patients with at least 1 diabetic foot ulcer. Patients were randomized to receive either Oasis Wound Matrix (n=37) or Regranex Gel (n=36) and a secondary dressing. Wounds were cleansed and débrided, if needed, at a weekly visit. The maximum treatment period for each patient was 12 weeks. After 12 weeks, 18 (49%) Oasis-treated patients had complete wound closure compared with 10 (28%) Regranex-treated patients. Oasis treatment met the noninferiority margin but did not demonstrate that healing in the Oasis group was statistically superior (p=0.055). Post hoc subgroup analysis showed no significant difference in incidence of healing in patients with type 1 diabetes (33% vs 25%) but showed a significant improvement in patients with type 2 diabetes (63% vs 29%). There was also an increased healing of plantar ulcers in the Oasis group (52% vs 14%). These post hoc findings are considered hypothesis-generating. Additional study with a larger number of subjects is needed to compare the effect of Oasis treatment to current SOC.

**Autologous Grafting on HYAFF Scaffolds**
Uccioli et al (2011) reported a multicenter RCT of cultured expanded fibroblasts and keratinocytes grown on a HYAFF scaffold (benzyl ester of hyaluronic acid) compared with paraffin gauze for difficult diabetic foot ulcers.\(^{43}\) A total of 180 patients were randomized. At 12 weeks, complete ulcer healing was similar for the two groups (24% treated vs 21% controls). At 20 weeks, complete ulcer healing was achieved in a similar proportion of the treatment group (50%) and the control group (43%, log-rank test = 0.344). Subgroup analysis, adjusted for baseline factors and possibly post-hoc, found a statistically significant benefit of treatment on dorsal ulcers but not plantar ulcers.
Section Summary: Bioengineered Skin Substitutes Other Than Apligraf, Dermagraft, AlloPatch, or Integra for Diabetic Lower-Extremity Ulcers

Results from a multicenter RCT showed some benefit of DermACELL that was primarily for the subgroup of patients who only required a single application of the ADM. Studies are needed to further define the population who might benefit from this treatment. Additional study with a larger number of subjects is needed to evaluate the effect of Graftjacket, TheraSkin, DermACELL, Cytal, PriMatrix, and Oasis Wound Matrix, compared with current SOC or other advanced wound therapies.

Lower-Extremity Ulcers due to Venous Insufficiency

Apligraf

Falanga et al (1998) reported on a multicenter randomized trial of Apligraf living cell therapy.44 A total of 293 patients with venous insufficiency and clinical signs of venous ulceration were randomized to compression therapy alone or to compression therapy and treatment with Apligraf. Apligraf was applied up to a maximum of 5 (mean, 3.3) times per patient during the initial 3 weeks. The primary end points were the percentage of patients with complete healing by 6 months after initiation of treatment and the time required for complete healing. At 6-month follow-up, the percentage of patients healed was higher with Apligraf (63% vs 49%), and the median time to complete wound closure was shorter (61 days vs 181 days). Treatment with Apligraf was superior to compression therapy in healing larger (>1000 mm²) and deeper ulcers and ulcers of more than 6 months in duration. There were no symptoms or signs of rejection, and the occurrence of adverse events was similar in both groups. This study was reviewed in a 2001 TEC Assessment, which concluded that Apligraf (Graftskin), in conjunction with good local wound care, met TEC criteria for the treatment of venous ulcers that fail to respond to conservative management.22.

Oasis Wound Matrix

Mostow et al (2005) reported on an industry-sponsored multicenter (12 sites) randomized trial that compared weekly treatment using Oasis Wound Matrix (xenogenic collagen scaffold from porcine small intestinal mucosa) with SOC in 120 patients who had chronic ulcers due to venous insufficiency that had not adequately responding to conventional therapy.45 Healing was assessed weekly for up to 12 weeks, with follow-up performed after 6 months to assess recurrence. After 12 weeks of treatment, there was a significant improvement in the percentage of wounds healed in the Oasis group (55% vs 34%). After adjusting for baseline ulcer size, patients in the Oasis group were 3 times more likely to heal than those in the group receiving SOC. Patients in the SOC group whose wounds did not heal by week 12 were allowed to cross over to Oasis treatment. None of the healed patients treated with Oasis wound matrix who was seen for the 6-month follow-up experienced ulcer recurrence.

A research group in Europe has described 2 comparative studies of the Oasis matrix for mixed arteriovenous ulcers. In a 2007 quasirandomized study, Romanelli et al compared the efficacy of 2 extracellular matrix-based products, Oasis and Hyaloskin (extracellular matrix with hyaluronic acid).46 Fifty-four patients with mixed arteriovenous leg ulcers were assigned to the 2 arms based on order of entry into the study; 50 patients completed the study. Patients were followed twice weekly, and dressings changed more than once a week, only when necessary. After 16 weeks of treatment, complete wound closure was achieved in 82.6% of Oasis-treated ulcers compared with 46.2% of Hyaloskin-treated ulcers. Oasis treatment significantly increased the time to dressing change (mean, 6.4 days vs 2.4 days), reduced pain on a 10-point scale (3.7 vs 6.2), and improved patient comfort (2.5 vs 6.7).
In a 2010 trial, Romanelli et al compared Oasis with a moist wound dressing (SOC) in 23 patients with mixed arteriovenous ulcers and 27 patients with venous ulcers.\textsuperscript{47} The trial was described as randomized, but the method of randomization was not described. After the 8-week study period, patients were followed monthly for 6 months to assess wound closure. Complete wound closure was achieved in 80\% of the Oasis-treated ulcers at 8 weeks compared with 65\% of the SOC group. On average, Oasis-treated ulcers achieved complete healing in 5.4 weeks compared with 8.3 weeks for the SOC group. Treatment with Oasis also increased the time to dressing change (5.2 days vs 2.1 days) and the percentage of granulation tissue formed (65\% vs 38\%).

**Subsection Summary: Apligraf or Oasis Wound Matrix for Lower-Extremity Ulcers due to Venous Insufficiency**

RCTs have demonstrated the efficacy of Apligraf or Oasis Wound Matrix over SOC for lower-extremity ulcers due to venous insufficiency. Evidence is considered sufficient for these products.

**Bioengineered Skin Substitutes Other Than Apligraf or Oasis Wound Matrix for Lower-Extremity Ulcers due to Venous Insufficiency**

**Dermagraft**

Dermagraft living cell therapy has been approved by FDA for repair of diabetic foot ulcers. Use of Dermagraft for venous ulcers is an off-label indication. In 2013, Harding et al reported an open-label multicenter RCT that compared Dermagraft plus compression therapy (n=186) with compression therapy alone (n=180).\textsuperscript{48} The trial had numerous inclusion and exclusion criteria that restricted the population to patients who had nonhealing ulcers with compression therapy but had the capacity to heal. ITT analysis revealed no significant difference between the 2 groups in the primary outcome measure, the proportion of patients with completely healed ulcers by 12 weeks (34\% Dermagraft vs 31\% control). Prespecified subgroup analysis revealed a significant improvement in the percentage of wounds healed for ulcers of 12 months or less in duration (52\% vs 37\%) and for ulcers of 10 cm or less in diameter (47\% vs 39\%). There were no significant differences in the secondary outcomes of time to healing, complete healing by week 24, and percent reduction in ulcer area.

**PriMatrix**

In 2011, Karr published a retrospective comparison of PriMatrix (xenogenic ADM) and Apligraf in 28 venous stasis ulcers.\textsuperscript{41} The first 14 venous stasis ulcers matching the inclusion and exclusion criteria for each graft were compared. Criteria were venous stasis ulcers of 4 weeks in duration, at least 1 cm\(^2\) in diameter, and to a depth of subcutaneous tissue, with healthy tissue at the ulcer edge, adequate arterial perfusion to heal, and ability to tolerate compression therapy. The time to complete healing for PriMatrix was 32 days with 1.3 applications compared with 63 days with 1.7 applications for Apligraf. Although promising, additional study with a larger number of subjects is needed to assess the effect of PriMatrix treatment in compared with current SOC.

**Section Summary: Bioengineered Skin Substitutes Other Than Apligraf or Oasis Wound Matrix for Lower-Extremity Ulcers due to Venous Insufficiency**

In a moderately large RCT, Dermagraft was not shown to be more effective than controls in the primary or secondary end points for the entire population and was slightly more effective than controls (an 8\%-15\% increase in healing) only in subgroups of patients with ulcer duration of 12 months or less or wound diameter of 10 cm or less. Additional study with a larger number of subjects is needed to evaluate the effect of PriMatrix treatment compared with current SOC.
Dystrophic Epidermolysis Bullosa
OrCel was approved under an humanitarian device exemption (HDE) for use in patients with dystrophic epidermolysis bullosa undergoing hand reconstruction surgery, to close and heal wounds created by the surgery, including those at donor sites. HDE status has been withdrawn for Dermagraft for this indication.

Fivenson et al (2003) reported the off-label use of Apligraf in 5 patients with recessive dystrophic epidermolysis bullosa who underwent syndactyly release.49

Section Summary: Dystrophic Epidermolysis Bullosa
Dystrophic epidermolysis bullosa is a rare disorder. Because this is a rare disorder, it is unlikely that RCTs will be conducted to evaluate whether OrCel improves health outcomes for this condition. Therefore, the HDE for OrCel is considered sufficient.

Deep Dermal Burns
Epicel
One case series from 2000 has described the treatment of 30 severely burned patients with Epicel.50 The cultured epithelial autografts were applied to a mean of 37% of total body surface area (TBSA). Epicel achieved permanent coverage of a mean of 26% of TBSA, an area similar to that covered by conventional autografts (mean, 25%). Survival was 90% in these severely burned patients.

Integra Dermal Regeneration Template
A 2013 study compared Integra with split-thickness skin graft and with viscose cellulose sponge (Cellonex), using three 10×5 cm test sites on each of 10 burn patients.51 The surrounding burn area was covered with meshed autograft. Biopsies were taken from each site on days 3, 7, 14, and 21, and at months 3 and 12. The tissue samples were stained and examined for markers of inflammation and proliferation. The Vancouver Scar Scale was used to assess scars. At 12-month follow-up, the 3 methods resulted in similar clinical appearance, along with similar histologic and immunohistochemical findings.

Branski et al (2007) reported on a randomized trial that compared Integra with a standard autograft-allograft technique in 20 children with an average burn size of 73% TBSA (71% full-thickness burns).52 Once vascularized (about 14-21 days), the Silastic epidermis was stripped and replaced with thin (0.05-0.13 mm) epidermal autograft. There were no significant differences between the Integra group and controls in burn size (70% vs 74% TBSA), mortality (40% vs 30%), and hospital length of stay (41 vs 39 days), all respectively. Long-term follow-up revealed a significant increase in bone mineral content and density (24 months) and improved scarring in terms of height, thickness, vascularity, and pigmentation (at 12 months and 18-24 months) in the Integra group. No differences were observed between groups in the time to first reconstructive procedure, cumulative reconstructive procedures required during 2 years, and cumulative operating room time required for these procedures. The authors concluded that Integra can be used for immediate wound coverage in children with severe burns without the associated risks of cadaver skin.

Heimbach et al (2003) reported on a multicenter (13 U.S. burn care facilities) postapproval study involving 222 burn injury patients (36.5% TBSA; range, 1%-95%) who were treated with Integra Dermal Regeneration Template.53 Within 2 to 3 weeks, the dermal layer regenerated, and a thin epidermal autograft was placed over the wound. The incidence of infection was 16.3%. Mean

Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information
take rate (absence of graft failure) of Integra was 76.2%; the median take rate was 98%. The mean take rate of epidermal autograft placed over Integra was 87.7%; the median take rate was 95%.

**TransCyte**

TransCyte is no longer commercially available.

Earlier studies included a 2001 report by Lukish et al that found improved healing in 20 consecutive cases of pediatric burns greater than 7% TBSA that underwent wound closure using TransCyte compared to the previous 20 consecutive burn cases greater than 7% TBSA that received standard therapy. In 2006, Amani et al found significant improvement in healing in 110 consecutive patients who had deep partial-thickness burns treated with TransCyte as compared to results from the American Burn Association Patient Registry for similar burns.

**Section Summary: Deep Dermal Burns**

Epicel is FDA-approved under an HDE for the treatment of deep dermal or full-thickness burns comprising a TBSA of 30% or more, with patient survival of 90%. Integra Dermal Regeneration Template has been compared with autograft in a within-subject study and with autograft-allograft in a small RCT with 10 patients per group. Outcomes are at least as good as with autograft or allograft, with a reduction in scarring and without risks associated with cadaver skin. This product has also been studied in a large series with over 222 burn patients, showing a take rate of 76% and with a take rate of epidermal autograft placed over Integra of 87.7%.

**Other Indications**

**Punch Biopsy Wounds**

Baldursson et al (2015) reported a double-blinded RCT with 81 patients (162 punch biopsy wounds) that compared Kerecis Omega3 Wound (derived from fish skin) with Oasis SIS ECM (porcine small intestinal submucosa extracellular matrix). The primary outcome (the percentage of wounds healed at 28 days) was similar for the fish skin ADM (95%) and the porcine SIS ECM (96.3%). The rate of healing was faster with Kerecis Omega3 (p=0.041). At 21 days, 72.5% of the fish skin ADM group had healed compared with 56% of the porcine SIS ECM group. Interpretation of this study is limited because it did not include an accepted control condition for this indication.

**Split-Thickness Donor Sites**

There is limited evidence to support the efficacy of OrCel compared with SOC for the treatment of split-thickness donor sites in burn patients. In 2003, Stilet al examined the safety and efficacy of bilayered OrCel to facilitate wound closure of split-thickness donor sites in 82 severely burned patients. Each patient had 2 designated donor sites that were randomized to a single treatment of OrCel or standard dressing (Biobrane-L). The healing time for OrCel sites was significantly shorter than for sites treated with a standard dressing, enabling earlier recropping. OrCel sites also exhibited a nonsignificant trend for reduced scarring. Additional studies are needed to evaluate the effect of this product on health outcomes.

**Miscellaneous**

In addition to indications previously reviewed, off-label uses of bioengineered skin substitutes have included pressure ulcers, inflammatory ulcers (eg, pyoderma gangrenosum, vasculitis), scleroderma digital ulcers, postkeloid removal wounds, genetic conditions, and variety of other conditions. Products that have been FDA-approved or -cleared for one indication (eg, lower-
extremity ulcers) have also been used off-label in place of other FDA-approved or -cleared products (eg, for burns).\textsuperscript{59} No controlled trials were identified for these indications.

**Summary of Evidence**

**Breast Reconstruction**

For individuals who are undergoing breast reconstruction who receive allogeneic ADM products, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. A systematic review found no difference in overall complication rates with ADM allograft compared with standard procedures for breast reconstruction. Reconstructions with ADM have been reported to have higher seroma, infection, and necrosis rates than reconstructions without ADM. However, capsular contracture and malposition of implants may be reduced. Thus, in cases where there is limited tissue coverage, the available evidence may inform patient decision making about reconstruction options. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Tendon Repair**

For individuals who are undergoing tendon repair who receive Graftjacket, the evidence includes an RCT. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. The RCT identified found improved outcomes with the Graftjacket ADM allograft for rotator cuff repair. Although these results were positive, additional study with a larger number of patients is needed to evaluate the consistency of the effect. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Surgical Repair of Hernias or Parastomal Reinforcement**

For individuals who are undergoing surgical repair of hernias or parastomal reinforcement who receive acellular collagen-based scaffolds, the evidence includes RCTs. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. Several comparative studies including RCTs have shown no difference in outcomes between tissue-engineered skin substitutes and either standard synthetic mesh or no reinforcement. The evidence is sufficient to determine that the technology is unlikely to improve the net health outcome.

**Diabetic Lower-Extremity Ulcers**

For individuals who have diabetic lower-extremity ulcers who receive AlloPatch, Apligraf, Dermagraft, or Integra, the evidence includes RCTs. Relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, and quality of life. RCTs have demonstrated the efficacy of AlloPatch (reticular ADM), Apligraf and Dermagraft (living cell therapy), and Integra (biosynthetic) over the standard of care. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have diabetic lower-extremity ulcers who receive ADM products other than AlloPatch, Apligraf, Dermagraft, or Integra, the evidence includes RCTs. Relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, and quality of life. Results from a multicenter RCT showed some benefit of DermACELL that was primarily for the subgroup of patients who only required a single application of the ADM. Studies are needed to further define the population who might benefit from this treatment. Additional study with a larger number of subjects is needed to evaluate the effect of Graftjacket, TheraSkin, DermACELL, Cytal, PriMatrix, and Oasis Wound Matrix, compared with current SOC or other advanced wound...
therapies. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Lower-Extremity Ulcers due to Venous Insufficiency**

For individuals who have lower-extremity ulcers due to venous insufficiency who receive Apligraf or Oasis Wound Matrix, the evidence includes RCTs. Relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, and quality of life. RCTs have demonstrated the efficacy of Apligraf living cell therapy and xenogenic Oasis Wound Matrix over the standard of care. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have lower-extremity ulcers due to venous insufficiency who receive bioengineered skin substitutes other than Apligraf or Oasis Wound Matrix, the evidence includes RCTs. Relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, and quality of life. In a moderately large RCT, Dermagraft was not shown to be more effective than controls for the primary or secondary end points in the entire population and was only slightly more effective than controls (an 8%-15% increase in healing) in subgroups of patients with ulcer durations of 12 months or less or size of 10 cm or less. Additional study with a larger number of subjects is needed to evaluate the effect of the xenogenic PriMatrix skin substitute vs the current standard of care. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Dystrophic Epidermolysis Bullosa**

For individuals who have dystrophic epidermolysis bullosa who receive OrCel, the evidence includes case series. Relevant outcomes are symptoms, change in disease status, morbid events, and quality of life. OrCel was approved under a humanitarian drug exemption for use in patients with dystrophic epidermolysis bullosa undergoing hand reconstruction surgery, to close and heal wounds created by the surgery, including those at donor sites. Outcomes have been reported in small series (eg, 5 patients). The evidence is insufficient to determine the effects of the technology on health outcomes.

**Deep Dermal Burns**

For individuals who have deep dermal burns who receive bioengineered skin substitutes (ie, Epicel, Integra Dermal Regeneration Template), the evidence includes RCTs. Relevant outcomes are disease-specific survival, symptoms, change in disease status, morbid events, functional outcomes, quality of life, and treatment-related morbidity. Overall, few skin substitutes have been approved, and the evidence is limited for each product. Epicel (living cell therapy) has received FDA approval under a humanitarian device exemption for the treatment of deep dermal or full-thickness burns comprising a total body surface area of 30% or more. Comparative studies have demonstrated improved outcomes for biosynthetic skin substitute Integra Dermal Regeneration Template for the treatment of burns. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

**Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.
2016 Input
In response to requests, input was received from 2 physician specialty societies and 3 academic medical centers while this policy was under review in 2016. Input was requested on the equivalency of products within the categories of amniotic membrane, living cell therapies, and biosynthetic skin substitutes for the treatment of diabetic foot ulcers and nonocular burns (biosynthetic only). Input on the equivalency of products within these categories was mixed.

2014 Input
In response to requests, input was received from 3 physician specialty societies and 4 academic medical centers while this policy was under review in 2014. In addition to questions on medical necessity for different indications, input was specifically requested on the equivalency of products within the different categories (eg, acellular dermal matrix [ADM], living cell therapy, xenogeneic collagen scaffold, amniotic membrane). Five reviewers addressed the use of ADM products for breast reconstruction and most considered the various ADM products (AlloDerm, AlloMax, DermaMatrix, FlexHD, Graftjacket) to have similar outcomes when used for breast reconstructive surgery, although differences in firmness and stretch of the products were noted. Six reviewers addressed questions on bioengineered skin and soft tissue substitutes for diabetic and venous lower-extremity ulcers. Responses were mixed, although most reviewers considered living cell therapies to be equivalent for these indications. Most reviewers did not consider xenogeneic ADM products (eg, PriMatrix) or amniotic membrane (eg, EpiFix) to be medically necessary for any indication.

2012 Input
In response to requests, input was received from 3 physician specialty societies and 2 academic medical centers while this policy was under review in 2012. Most reviewers supported the indications and products described in this policy. Input was requested on the use of an interpositional spacer after parotidectomy. Support for this indication was mixed. Some reviewers suggested use of other products and/or additional indications; however, the input on these products/indications was not uniform. Reviewers provided references for the additional indications; these were subsequently reviewed.

2009 Input
In response to requests, input was received from 1 physician specialty society (2 physicians) and 1 academic medical center while this policy was under review in 2009. All reviewers indicated that use of AlloDerm in breast reconstruction surgery should be available for use during breast reconstructive surgery.

Practice Guidelines and Position Statements

American Society of Plastic Surgeons and Wound Healing Society
A literature review for the 2013 guidelines from the American Society of Plastic Surgeons (ASPS) found that use of ADM, although increasingly common in postmastectomy expander/implant breast reconstruction, can result in increased risk of complications in the presence of certain risk factors. ASPS noted that cellular dermal matrix is currently used to increase soft tissue coverage, support the implant pocket, improve contour, and reduce pain with expansion. However, evidence to support these improved surgical outcomes are limited. Some evidence has suggested that use of ADM is associated with increased postoperative complications, specifically related to infection and seroma. Overall, ASPS found that evidence on ADM products in postmastectomy expander/implant breast reconstruction was varied and conflicting, and gave a
grade C recommendation based on level III evidence that surgeons should evaluate each clinical case individually and objectively determine the use of ADM.

**National Institute for Health and Care Excellence**
In 2016, the National Institute for Health and Care Excellence updated its guidance on the prevention and management of diabetic foot problems. The Institute recommended that clinicians "consider dermal or skin substitutes as an adjunct to standard care when treating diabetic foot ulcers, only when healing has not progressed and on the advice of the multidisciplinary foot care service."

**Infectious Diseases Society of America**
The 2012 guidelines from the Infectious Diseases Society of America stated that, for selected diabetic foot wounds that are slow to heal, clinicians might consider using bioengineered skin equivalents (weak recommendation, moderate evidence), growth factors (weak, moderate), granulocyte colony-stimulating factors (weak, moderate), hyperbaric oxygen therapy (strong, moderate), or negative pressure wound therapy (weak, low). It was emphasized that none of these measures had been shown to improve the resolution of infection and that they were expensive, not universally available, might require consultation with experts, and reports supporting their utility were mostly flawed.

**U.S. Preventive Services Task Force Recommendations**
Not applicable.

**Ongoing and Unpublished Clinical Trials**
Some currently unpublished trials that might influence this review are listed in Table 6.

### Table 6. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01987700a</td>
<td>Multi-Center Study To Examine The Use Of Flex HD® And Strattice In The Repair Of Large Abdominal Wall Hernias</td>
<td>120</td>
<td>Oct 2017 (ongoing)</td>
</tr>
<tr>
<td>NCT02587403a</td>
<td>A Randomized, Prospective Study Comparing Fortiva™ Porcine Dermis vs. Strattice™ Reconstructive Tissue Matrix in Patients Undergoing Complex Open Primary Ventral Hernia Repair</td>
<td>120</td>
<td>Oct 2019</td>
</tr>
<tr>
<td>NCT02322554</td>
<td>The Registry of Cellular and Tissue Based Therapies for Chronic Wounds and Ulcers</td>
<td>50,000</td>
<td>Jan 2020</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01970163a</td>
<td>A Multicenter, Randomized, Controlled, Open Label Trial of DermACELL in Subjects With Chronic Wounds of the Lower Extremities</td>
<td>202</td>
<td>Apr 2016 (completed)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

*a Denotes industry-sponsored or cosponsored trial.
## CODING

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

### CPT

**Autografts and Tissue-cultured Autografts**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15040</td>
<td>Harvest of skin for tissue cultured skin autograft, 100 sq cm or less</td>
</tr>
<tr>
<td>15050</td>
<td>Pinch graft, single or multiple, to cover small ulcer, tip of digit, or other minimal open area (except on face), up to defect size 2 cm diameter</td>
</tr>
<tr>
<td>15100</td>
<td>Split-thickness autograft, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children (except 15050)</td>
</tr>
<tr>
<td>15101</td>
<td>Split-thickness autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>15110</td>
<td>Epidermal autograft, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children</td>
</tr>
<tr>
<td>15111</td>
<td>Epidermal autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>15115</td>
<td>Epidermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children</td>
</tr>
<tr>
<td>15116</td>
<td>Epidermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>15120</td>
<td>Split-thickness autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children (except 15050)</td>
</tr>
<tr>
<td>15121</td>
<td>Split-thickness autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>15130</td>
<td>Dermal autograft, trunk, arms, legs; first 100 sq cm or less, or 1% of body area of infants and children</td>
</tr>
<tr>
<td>15131</td>
<td>Dermal autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>15135</td>
<td>Dermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 100 sq cm or less, or 1% of body area of infants and children</td>
</tr>
<tr>
<td>15136</td>
<td>Dermal autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>15150</td>
<td>Tissue cultured skin autograft, trunk, arms, legs; first 25 sq cm or less</td>
</tr>
<tr>
<td>15151</td>
<td>Tissue cultured skin autograft, trunk, arms, legs; additional 1 sq cm to 75 sq cm (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>15152</td>
<td>Tissue cultured skin autograft, trunk, arms, legs; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>
15155  Tissue cultured skin autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; first 25 sq cm or less
15156  Tissue cultured skin autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; additional 1 sq cm to 75 sq cm (List separately in addition to code for primary procedure)
15157  Tissue cultured skin autograft, face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits; each additional 100 sq cm, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)
15200  Full thickness graft, free, including direct closure of donor site, trunk; 20 sq cm or less
15201  Full thickness graft, free, including direct closure of donor site, trunk; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)
15220  Full thickness graft, free, including direct closure of donor site, scalp, arms, and/or legs; 20 sq cm or less
15221  Full thickness graft, free, including direct closure of donor site, scalp, arms, and/or legs; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)
15240  Full thickness graft, free, including direct closure of donor site, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands, and/or feet; 20 sq cm or less
15241  Full thickness graft, free, including direct closure of donor site, forehead, cheeks, chin, mouth, neck, axillae, genitalia, hands, and/or feet; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)
15260  Full thickness graft, free, including direct closure of donor site, nose, ears, eyelids, and/or lips; 20 sq cm or less
15261  Full thickness graft, free, including direct closure of donor site, nose, ears, eyelids, and/or lips; each additional 20 sq cm, or part thereof (List separately in addition to code for primary procedure)

Skin Substitute Grafts
15271  Application of skin substitute graft to trunk, arms, legs total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
15272  Application of skin substitute graft to trunk, arms, legs total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)
15273  Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children
15274  Application of skin substitute graft to trunk, arms, legs, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)
15275  Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area
15276  Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; each additional 25 sq cm wound surface area, or part thereof (List separately in addition to code for primary procedure)
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>15277</td>
<td>Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; first 100 sq cm wound surface area, or 1% of body area of infants and children</td>
</tr>
<tr>
<td>15278</td>
<td>Application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area greater than or equal to 100 sq cm; each additional 100 sq cm wound surface area, or part thereof, or each additional 1% of body area of infants and children, or part thereof (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>15777</td>
<td>Implantation of biologic implant (eg, acellular dermal matrix) for soft tissue reinforcement (eg, breast, trunk) (List separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>

**HCPCS**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9354</td>
<td>Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm</td>
</tr>
<tr>
<td>C9356</td>
<td>Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (TenoGlide Tendon Protector Sheet), per sq cm</td>
</tr>
<tr>
<td>C9358</td>
<td>Dermal substitute, native, non-denatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm</td>
</tr>
<tr>
<td>C9360</td>
<td>Dermal substitute, native, non-denatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm</td>
</tr>
<tr>
<td>C9363</td>
<td>Skin substitute (Integra Meshed Bilayer Wound Matrix), per square cm</td>
</tr>
<tr>
<td>C9364</td>
<td>Porcine implant, Permacol, per sq cm</td>
</tr>
<tr>
<td>Q4100</td>
<td>Skin substitute, not otherwise specified</td>
</tr>
<tr>
<td>Q4101</td>
<td>Apligraf, per sq cm</td>
</tr>
<tr>
<td>Q4102</td>
<td>Oasis wound matrix, per sq cm</td>
</tr>
<tr>
<td>Q4103</td>
<td>Oasis burn matrix, per sq cm</td>
</tr>
<tr>
<td>Q4104</td>
<td>Integra bilayer matrix wound dressing (BMWD), per sq cm</td>
</tr>
<tr>
<td>Q4105</td>
<td>Integra dermal regeneration template (DRT) or Integra Omnigraft dermal regeneration matrix, per sq cm</td>
</tr>
<tr>
<td>Q4106</td>
<td>Dermagraft, per sq cm</td>
</tr>
<tr>
<td>Q4107</td>
<td>GRAFTJACKET, per sq cm</td>
</tr>
<tr>
<td>Q4108</td>
<td>Integra matrix, per sq cm</td>
</tr>
<tr>
<td>Q4110</td>
<td>PriMatrix, per sq cm</td>
</tr>
<tr>
<td>Q4111</td>
<td>GammaGraft, per sq cm</td>
</tr>
<tr>
<td>Q4112</td>
<td>Cymetra, injectable, 1 cc</td>
</tr>
<tr>
<td>Q4113</td>
<td>GRAFTJACKET XPRESS, injectable, 1cc</td>
</tr>
<tr>
<td>Q4114</td>
<td>Integra flowable wound matrix, injectable, 1 cc</td>
</tr>
<tr>
<td>Q4115</td>
<td>AlloSkin, per sq cm</td>
</tr>
<tr>
<td>Q4116</td>
<td>AlloDerm, per sq cm</td>
</tr>
<tr>
<td>Q4117</td>
<td>HYALOMATRIX, per sq cm</td>
</tr>
<tr>
<td>Q4118</td>
<td>MatriStem micromatrix, 1 mg</td>
</tr>
<tr>
<td>Q4121</td>
<td>TheraSkin, per sq cm</td>
</tr>
<tr>
<td>Q4122</td>
<td>DermACELL, DermACELL AWM or DermACELL AWM Porous, per sq cm</td>
</tr>
<tr>
<td>Q4123</td>
<td>AlloSkin RT, per sq cm</td>
</tr>
<tr>
<td>Q4124</td>
<td>OASIS ultra tri-layer wound matrix, per sq cm</td>
</tr>
<tr>
<td>Q4125</td>
<td>ArthroFlex, per sq cm</td>
</tr>
<tr>
<td>Q4126</td>
<td>MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm</td>
</tr>
<tr>
<td>Q4127</td>
<td>Talymed, per sq cm</td>
</tr>
<tr>
<td>Q4128</td>
<td>FlexHD, AllopatchHD, or Matrix HD, per sq cm</td>
</tr>
<tr>
<td>Q4130</td>
<td>Strattice TM, per sq cm</td>
</tr>
<tr>
<td>Q4134</td>
<td>hMatrix, per sq cm</td>
</tr>
<tr>
<td>Q4135</td>
<td>Mediskin, per sq cm</td>
</tr>
</tbody>
</table>


Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information
Application of skin replacements and skin substitutes is reported with CPT codes 15040-15278.

- Codes 15040-15261 are specific to autografts and tissue-cultured autografts.
- Codes 15271-15278 are specific to skin substitutes grafts.
- There is a specific add-on CPT code for the use of these materials as an implant: 15777.
- The HCPCS codes for these products used in outpatient and office settings are listed in the code table. There are also HCPCS modifiers to indicate whether the skin substitute is or is not used as a graft (ie, surface use vs use as an implant):
  - JC: Skin substitute used as a graft
  - JD: Skin substitute not used as a graft

**ICD-10 Diagnoses (Effective October 1, 2015)**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C50.011</td>
<td>Malignant neoplasm of nipple and areola, right female breast</td>
</tr>
<tr>
<td>C50.012</td>
<td>Malignant neoplasm of nipple and areola, left female breast</td>
</tr>
<tr>
<td>C50.111</td>
<td>Malignant neoplasm of central portion of right female breast</td>
</tr>
<tr>
<td>C50.112</td>
<td>Malignant neoplasm of central portion of left female breast</td>
</tr>
<tr>
<td>C50.211</td>
<td>Malignant neoplasm of upper-inner quadrant of right female breast</td>
</tr>
<tr>
<td>C50.212</td>
<td>Malignant neoplasm of upper-inner quadrant of left female breast</td>
</tr>
<tr>
<td>C50.311</td>
<td>Malignant neoplasm of lower-inner quadrant of right female breast</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>C50.312</td>
<td>Malignant neoplasm of lower-inner quadrant of left female breast</td>
</tr>
<tr>
<td>C50.411</td>
<td>Malignant neoplasm of upper-outer quadrant of right female breast</td>
</tr>
<tr>
<td>C50.412</td>
<td>Malignant neoplasm of upper-outer quadrant of left female breast</td>
</tr>
<tr>
<td>C50.511</td>
<td>Malignant neoplasm of lower-outer quadrant of right female breast</td>
</tr>
<tr>
<td>C50.512</td>
<td>Malignant neoplasm of lower-outer quadrant of left female breast</td>
</tr>
<tr>
<td>C50.611</td>
<td>Malignant neoplasm of axillary tail of right female breast</td>
</tr>
<tr>
<td>C50.612</td>
<td>Malignant neoplasm of axillary tail of left female breast</td>
</tr>
<tr>
<td>C50.811</td>
<td>Malignant neoplasm of overlapping sites of right female breast</td>
</tr>
<tr>
<td>C50.812</td>
<td>Malignant neoplasm of overlapping sites of left female breast</td>
</tr>
<tr>
<td>D05.01</td>
<td>Lobular carcinoma in situ of right breast</td>
</tr>
<tr>
<td>D05.02</td>
<td>Lobular carcinoma in situ of left breast</td>
</tr>
<tr>
<td>D05.11</td>
<td>Intraductal carcinoma in situ of right breast</td>
</tr>
<tr>
<td>D05.12</td>
<td>Intraductal carcinoma in situ of left breast</td>
</tr>
<tr>
<td>D05.81</td>
<td>Other specified type of carcinoma in situ of right breast</td>
</tr>
<tr>
<td>D05.82</td>
<td>Other specified type of carcinoma in situ of left breast</td>
</tr>
<tr>
<td>E10.40</td>
<td>Type 1 diabetes mellitus with diabetic neuropathy, unspecified</td>
</tr>
<tr>
<td>E10.41</td>
<td>Type 1 diabetes mellitus with diabetic mononeuropathy</td>
</tr>
<tr>
<td>E10.42</td>
<td>Type 1 diabetes mellitus with diabetic polyneuropathy</td>
</tr>
<tr>
<td>E10.43</td>
<td>Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy</td>
</tr>
<tr>
<td>E10.44</td>
<td>Type 1 diabetes mellitus with diabetic amyotrophy</td>
</tr>
<tr>
<td>E10.49</td>
<td>Type 1 diabetes mellitus with other diabetic neurological complication</td>
</tr>
<tr>
<td>E10.610</td>
<td>Type 1 diabetes mellitus with diabetic neuropathic arthropathy</td>
</tr>
<tr>
<td>E10.618</td>
<td>Type 1 diabetes mellitus with other diabetic arthropathy</td>
</tr>
<tr>
<td>E10.621</td>
<td>Type 1 diabetes mellitus with foot ulcer</td>
</tr>
<tr>
<td>E10.69</td>
<td>Type 1 diabetes mellitus with other specified complication</td>
</tr>
<tr>
<td>E11.40</td>
<td>Type 2 diabetes mellitus with diabetic neuropathy, unspecified</td>
</tr>
<tr>
<td>E11.41</td>
<td>Type 2 diabetes mellitus with diabetic mononeuropathy</td>
</tr>
<tr>
<td>E11.42</td>
<td>Type 2 diabetes mellitus with diabetic polyneuropathy</td>
</tr>
<tr>
<td>E11.43</td>
<td>Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy</td>
</tr>
<tr>
<td>E11.44</td>
<td>Type 2 diabetes mellitus with diabetic amyotrophy</td>
</tr>
<tr>
<td>E11.49</td>
<td>Type 2 diabetes mellitus with other diabetic neurological complication</td>
</tr>
<tr>
<td>E11.610</td>
<td>Type 2 diabetes mellitus with diabetic neuropathic arthropathy</td>
</tr>
<tr>
<td>E11.618</td>
<td>Type 2 diabetes mellitus with other diabetic arthropathy</td>
</tr>
<tr>
<td>E11.621</td>
<td>Type 2 diabetes mellitus with foot ulcer</td>
</tr>
<tr>
<td>E11.69</td>
<td>Type 2 diabetes mellitus with other specified complication</td>
</tr>
<tr>
<td>E13.40</td>
<td>Other specified diabetes mellitus with diabetic neuropathy, unspecified</td>
</tr>
<tr>
<td>E13.41</td>
<td>Other specified diabetes mellitus with diabetic mononeuropathy</td>
</tr>
<tr>
<td>E13.42</td>
<td>Other specified diabetes mellitus with diabetic polyneuropathy</td>
</tr>
<tr>
<td>E13.43</td>
<td>Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy</td>
</tr>
<tr>
<td>E13.44</td>
<td>Other specified diabetes mellitus with diabetic amyotrophy</td>
</tr>
<tr>
<td>E13.49</td>
<td>Other specified diabetes mellitus with other diabetic neurological complication</td>
</tr>
<tr>
<td>E13.610</td>
<td>Other specified diabetes mellitus with diabetic neuropathic arthropathy</td>
</tr>
<tr>
<td>E13.618</td>
<td>Other specified diabetes mellitus with other diabetic arthropathy</td>
</tr>
<tr>
<td>E13.621</td>
<td>Other specified diabetes mellitus with foot ulcer</td>
</tr>
<tr>
<td>E13.69</td>
<td>Other specified diabetes mellitus with other specified complication</td>
</tr>
<tr>
<td>I83.011</td>
<td>Varicose veins of right lower extremity with ulcer of thigh</td>
</tr>
<tr>
<td>I83.012</td>
<td>Varicose veins of right lower extremity with ulcer of calf</td>
</tr>
<tr>
<td>I83.013</td>
<td>Varicose veins of right lower extremity with ulcer of ankle</td>
</tr>
<tr>
<td>I83.014</td>
<td>Varicose veins of right lower extremity with ulcer of heel and midfoot</td>
</tr>
<tr>
<td>I83.015</td>
<td>Varicose veins of right lower extremity with ulcer other part of foot</td>
</tr>
<tr>
<td>I83.018</td>
<td>Varicose veins of right lower extremity with ulcer other part of lower leg</td>
</tr>
<tr>
<td>I83.021</td>
<td>Varicose veins of left lower extremity with ulcer of thigh</td>
</tr>
<tr>
<td>I83.022</td>
<td>Varicose veins of left lower extremity with ulcer of calf</td>
</tr>
<tr>
<td>I83.023</td>
<td>Varicose veins of left lower extremity with ulcer of ankle</td>
</tr>
</tbody>
</table>
I83.024 Varicose veins of left lower extremity with ulcer of heel and midfoot
I83.025 Varicose veins of left lower extremity with ulcer other part of foot
I83.028 Varicose veins of left lower extremity with ulcer other part of lower leg
I83.11 Varicose veins of right lower extremity with inflammation
I83.12 Varicose veins of left lower extremity with inflammation
I83.211 Varicose veins of right lower extremity with both ulcer of thigh and inflammation
I83.212 Varicose veins of right lower extremity with both ulcer of calf and inflammation
I83.213 Varicose veins of right lower extremity with both ulcer of ankle and inflammation
I83.214 Varicose veins of right lower extremity with both ulcer of heel and midfoot and inflammation
I83.215 Varicose veins of right lower extremity with both ulcer other part of foot and inflammation
I83.218 Varicose veins of right lower extremity with both ulcer of other part of lower extremity and inflammation
I83.221 Varicose veins of left lower extremity with both ulcer of thigh and inflammation
I83.222 Varicose veins of left lower extremity with both ulcer of calf and inflammation
I83.223 Varicose veins of left lower extremity with both ulcer of ankle and inflammation
I83.224 Varicose veins of left lower extremity with both ulcer of heel and midfoot and inflammation
I83.225 Varicose veins of left lower extremity with both ulcer other part of foot and inflammation
I83.228 Varicose veins of left lower extremity with both ulcer of other part of lower extremity and inflammation
I87.2 Venous insufficiency (chronic) (peripheral)
L89.006 Pressure-induced deep tissue damage of unspecified elbow
L89.010 Pressure ulcer of right elbow, unstageable
L89.012 Pressure ulcer of right elbow, stage 2
L89.013 Pressure ulcer of right elbow, stage 3
L89.014 Pressure ulcer of right elbow, stage 4
L89.016 Pressure-induced deep tissue damage of right elbow
L89.020 Pressure ulcer of left elbow, unstageable
L89.022 Pressure ulcer of left elbow, stage 2
L89.023 Pressure ulcer of left elbow, stage 3
L89.024 Pressure ulcer of left elbow, stage 4
L89.026 Pressure-induced deep tissue damage of left elbow
L89.110 Pressure ulcer of right upper back, unstageable
L89.112 Pressure ulcer of right upper back, stage 2
L89.113 Pressure ulcer of right upper back, stage 3
L89.114 Pressure ulcer of right upper back, stage 4
L89.116 Pressure-induced deep tissue damage of right upper back
L89.120 Pressure ulcer of left upper back, unstageable
L89.122 Pressure ulcer of left upper back, stage 2
L89.123 Pressure ulcer of left upper back, stage 3
L89.124 Pressure ulcer of left upper back, stage 4
L89.126 Pressure-induced deep tissue damage of left upper back
L89.130 Pressure ulcer of right lower back, unstageable
L89.132 Pressure ulcer of right lower back, stage 2
L89.133 Pressure ulcer of right lower back, stage 3
L89.134 Pressure ulcer of right lower back, stage 4
L89.136 Pressure-induced deep tissue damage of right lower back
L89.140 Pressure ulcer of left lower back, unstageable
L89.142 Pressure ulcer of left lower back, stage 2
L89.143 Pressure ulcer of left lower back, stage 3
L89.144 Pressure ulcer of left lower back, stage 4
L89.146 Pressure-induced deep tissue damage of left lower back
L89.150 Pressure ulcer of sacral region, unstageable
L89.152 Pressure ulcer of sacral region, stage 2
L89.153 Pressure ulcer of sacral region, stage 3
L89.154  Pressure ulcer of sacral region, stage 4
L89.156  Pressure-induced deep tissue damage of sacral region
L89.210  Pressure ulcer of right hip, unstageable
L89.212  Pressure ulcer of right hip, stage 2
L89.213  Pressure ulcer of right hip, stage 3
L89.214  Pressure ulcer of right hip, stage 4
L89.216  Pressure-induced deep tissue damage of right hip
L89.220  Pressure ulcer of left hip, unstageable
L89.222  Pressure ulcer of left hip, stage 2
L89.223  Pressure ulcer of left hip, stage 3
L89.224  Pressure ulcer of left hip, stage 4
L89.226  Pressure-induced deep tissue damage of left hip
L89.310  Pressure ulcer of right buttock, unstageable
L89.312  Pressure ulcer of right buttock, stage 2
L89.313  Pressure ulcer of right buttock, stage 3
L89.314  Pressure ulcer of right buttock, stage 4
L89.316  Pressure-induced deep tissue damage of right buttock
L89.320  Pressure ulcer of left buttock, unstageable
L89.322  Pressure ulcer of left buttock, stage 2
L89.323  Pressure ulcer of left buttock, stage 3
L89.324  Pressure ulcer of left buttock, stage 4
L89.326  Pressure-induced deep tissue damage of left buttock
L89.42   Pressure ulcer of contiguous site of back, buttock and hip, stage 2
L89.43   Pressure ulcer of contiguous site of back, buttock and hip, stage 3
L89.44   Pressure ulcer of contiguous site of back, buttock and hip, stage 4
L89.45   Pressure ulcer of contiguous site of back, buttock and hip, unstageable
L89.46   Pressure-induced deep tissue damage of contiguous site of back, buttock and hip
L89.510  Pressure ulcer of right ankle, unstageable
L89.512  Pressure ulcer of right ankle, stage 2
L89.513  Pressure ulcer of right ankle, stage 3
L89.514  Pressure ulcer of right ankle, stage 4
L89.516  Pressure-induced deep tissue damage of right ankle
L89.520  Pressure ulcer of left ankle, unstageable
L89.522  Pressure ulcer of left ankle, stage 2
L89.523  Pressure ulcer of left ankle, stage 3
L89.524  Pressure ulcer of left ankle, stage 4
L89.526  Pressure-induced deep tissue damage of left ankle
L89.610  Pressure ulcer of right heel, unstageable
L89.612  Pressure ulcer of right heel, stage 2
L89.613  Pressure ulcer of right heel, stage 3
L89.614  Pressure ulcer of right heel, stage 4
L89.616  Pressure-induced deep tissue damage of right heel
L89.620  Pressure ulcer of left heel, unstageable
L89.622  Pressure ulcer of left heel, stage 2
L89.623  Pressure ulcer of left heel, stage 3
L89.624  Pressure ulcer of left heel, stage 4
L89.626  Pressure-induced deep tissue damage of left heel
L89.810  Pressure ulcer of head, unstageable
L89.812  Pressure ulcer of head, stage 2
L89.813  Pressure ulcer of head, stage 3
L89.814  Pressure ulcer of head, stage 4
L89.816  Pressure-induced deep tissue damage of head
L89.890  Pressure ulcer of other site, unstageable
L89.892  Pressure ulcer of other site, stage 2
L89.893  Pressure ulcer of other site, stage 3
L89.894  Pressure ulcer of other site, stage 4
L89.896  Pressure-induced deep tissue damage of other site
L97.112  Non-pressure chronic ulcer of right thigh with fat layer exposed
L97.122  Non-pressure chronic ulcer of left thigh with fat layer exposed
L97.212  Non-pressure chronic ulcer of right calf with fat layer exposed
L97.222  Non-pressure chronic ulcer of left calf with fat layer exposed
L97.312  Non-pressure chronic ulcer of right ankle with fat layer exposed
L97.322  Non-pressure chronic ulcer of left ankle with fat layer exposed
L97.412  Non-pressure chronic ulcer of right heel and midfoot with fat layer exposed
L97.422  Non-pressure chronic ulcer of left heel and midfoot with fat layer exposed
L97.512  Non-pressure chronic ulcer of other part of right foot with fat layer exposed
L97.522  Non-pressure chronic ulcer of other part of left foot with fat layer exposed
L97.812  Non-pressure chronic ulcer of other part of right lower leg with fat layer exposed
L97.822  Non-pressure chronic ulcer of other part of left lower leg with fat layer exposed
L97.912  Non-pressure chronic ulcer of unspecified part of right lower leg with fat layer exposed
L97.922  Non-pressure chronic ulcer of unspecified part of left lower leg with fat layer exposed
L98.412  Non-pressure chronic ulcer of buttock with fat layer exposed
L98.422  Non-pressure chronic ulcer of back with fat layer exposed
L98.492  Non-pressure chronic ulcer of skin of other sites with fat layer exposed

Q81.2  Epidermolysis bullosa dystrophica

T20.211A  Burn of second degree of right ear [any part, except ear drum], initial encounter
T20.211D  Burn of second degree of right ear [any part, except ear drum], subsequent encounter
T20.211S  Burn of second degree of right ear [any part, except ear drum], sequela
T20.212A  Burn of second degree of left ear [any part, except ear drum], initial encounter
T20.212D  Burn of second degree of left ear [any part, except ear drum], subsequent encounter
T20.212S  Burn of second degree of left ear [any part, except ear drum], sequela
T20.22xA  Burn of second degree of lip(s), initial encounter
T20.22xD  Burn of second degree of lip(s), subsequent encounter
T20.22xS  Burn of second degree of lip(s), sequela
T20.23xA  Burn of second degree of chin, initial encounter
T20.23xD  Burn of second degree of chin, subsequent encounter
T20.23xS  Burn of second degree of chin, sequela
T20.24xA  Burn of second degree of nose (septum), initial encounter
T20.24xD  Burn of second degree of nose (septum), subsequent encounter
T20.24xS  Burn of second degree of nose (septum), sequela
T20.25xA  Burn of second degree of scalp [any part], initial encounter
T20.25xD  Burn of second degree of scalp [any part], subsequent encounter
T20.25xS  Burn of second degree of scalp [any part], sequela
T20.26xA  Burn of second degree of forehead and cheek, initial encounter
T20.26xD  Burn of second degree of forehead and cheek, subsequent encounter
T20.26xS  Burn of second degree of forehead and cheek, sequela
T20.27xA  Burn of second degree of neck, initial encounter
T20.27xD  Burn of second degree of neck, subsequent encounter
T20.27xS  Burn of second degree of neck, sequela
T20.29xA  Burn of second degree of multiple sites of head, face, and neck, initial encounter
T20.29xD  Burn of second degree of multiple sites of head, face, and neck, subsequent encounter
T20.29xS  Burn of second degree of multiple sites of head, face, and neck, sequela
T20.311A  Burn of third degree of right ear [any part, except ear drum], initial encounter
T20.311D  Burn of third degree of right ear [any part, except ear drum], subsequent encounter
T20.311S  Burn of third degree of right ear [any part, except ear drum], sequela
T20.312A  Burn of third degree of left ear [any part, except ear drum], initial encounter
T20.312D  Burn of third degree of left ear [any part, except ear drum], subsequent encounter
T20.312S  Burn of third degree of left ear [any part, except ear drum], sequela
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T20.32xA</td>
<td>Burn of third degree of lip(s), initial encounter</td>
</tr>
<tr>
<td>T20.32xD</td>
<td>Burn of third degree of lip(s), subsequent encounter</td>
</tr>
<tr>
<td>T20.32xS</td>
<td>Burn of third degree of lip(s), sequela</td>
</tr>
<tr>
<td>T20.33xA</td>
<td>Burn of third degree of chin, initial encounter</td>
</tr>
<tr>
<td>T20.33xD</td>
<td>Burn of third degree of chin, subsequent encounter</td>
</tr>
<tr>
<td>T20.33xS</td>
<td>Burn of third degree of chin, sequela</td>
</tr>
<tr>
<td>T20.34xA</td>
<td>Burn of third degree of nose (septum), initial encounter</td>
</tr>
<tr>
<td>T20.34xD</td>
<td>Burn of third degree of nose (septum), subsequent encounter</td>
</tr>
<tr>
<td>T20.34xS</td>
<td>Burn of third degree of nose (septum), sequela</td>
</tr>
<tr>
<td>T20.35xA</td>
<td>Burn of third degree of scalp [any part], initial encounter</td>
</tr>
<tr>
<td>T20.35xD</td>
<td>Burn of third degree of scalp [any part], subsequent encounter</td>
</tr>
<tr>
<td>T20.35xS</td>
<td>Burn of third degree of scalp [any part], sequela</td>
</tr>
<tr>
<td>T20.36xA</td>
<td>Burn of third degree of forehead and cheek, initial encounter</td>
</tr>
<tr>
<td>T20.36xD</td>
<td>Burn of third degree of forehead and cheek, subsequent encounter</td>
</tr>
<tr>
<td>T20.36xS</td>
<td>Burn of third degree of forehead and cheek, sequela</td>
</tr>
<tr>
<td>T20.37xA</td>
<td>Burn of third degree of neck, initial encounter</td>
</tr>
<tr>
<td>T20.37xD</td>
<td>Burn of third degree of neck, subsequent encounter</td>
</tr>
<tr>
<td>T20.37xS</td>
<td>Burn of third degree of neck, sequela</td>
</tr>
<tr>
<td>T20.39xA</td>
<td>Burn of third degree of multiple sites of head, face, and neck, initial encounter</td>
</tr>
<tr>
<td>T20.39xD</td>
<td>Burn of third degree of multiple sites of head, face, and neck, subsequent encounter</td>
</tr>
<tr>
<td>T20.39xS</td>
<td>Burn of third degree of multiple sites of head, face, and neck, sequela</td>
</tr>
<tr>
<td>T20.611A</td>
<td>Corrosion of second degree of right ear [any part, except ear drum], initial encounter</td>
</tr>
<tr>
<td>T20.611D</td>
<td>Corrosion of second degree of right ear [any part, except ear drum], subsequent encounter</td>
</tr>
<tr>
<td>T20.611S</td>
<td>Corrosion of second degree of right ear [any part, except ear drum], sequela</td>
</tr>
<tr>
<td>T20.612A</td>
<td>Corrosion of second degree of left ear [any part, except ear drum], initial encounter</td>
</tr>
<tr>
<td>T20.612D</td>
<td>Corrosion of second degree of left ear [any part, except ear drum], subsequent encounter</td>
</tr>
<tr>
<td>T20.612S</td>
<td>Corrosion of second degree of left ear [any part, except ear drum], sequela</td>
</tr>
<tr>
<td>T20.62xA</td>
<td>Corrosion of second degree of lip(s), initial encounter</td>
</tr>
<tr>
<td>T20.62xD</td>
<td>Corrosion of second degree of lip(s), subsequent encounter</td>
</tr>
<tr>
<td>T20.62xS</td>
<td>Corrosion of second degree of lip(s), sequela</td>
</tr>
<tr>
<td>T20.63xA</td>
<td>Corrosion of second degree of chin, initial encounter</td>
</tr>
<tr>
<td>T20.63xD</td>
<td>Corrosion of second degree of chin, subsequent encounter</td>
</tr>
<tr>
<td>T20.63xS</td>
<td>Corrosion of second degree of chin, sequela</td>
</tr>
<tr>
<td>T20.64xA</td>
<td>Corrosion of second degree of nose (septum), initial encounter</td>
</tr>
<tr>
<td>T20.64xD</td>
<td>Corrosion of second degree of nose (septum), subsequent encounter</td>
</tr>
<tr>
<td>T20.64xS</td>
<td>Corrosion of second degree of nose (septum), sequela</td>
</tr>
<tr>
<td>T20.65xA</td>
<td>Corrosion of second degree of scalp [any part], initial encounter</td>
</tr>
<tr>
<td>T20.65xD</td>
<td>Corrosion of second degree of scalp [any part], subsequent encounter</td>
</tr>
<tr>
<td>T20.65xS</td>
<td>Corrosion of second degree of scalp [any part], sequela</td>
</tr>
<tr>
<td>T20.66xA</td>
<td>Corrosion of second degree of forehead and cheek, initial encounter</td>
</tr>
<tr>
<td>T20.66xD</td>
<td>Corrosion of second degree of forehead and cheek, subsequent encounter</td>
</tr>
<tr>
<td>T20.66xS</td>
<td>Corrosion of second degree of forehead and cheek, sequela</td>
</tr>
<tr>
<td>T20.67xA</td>
<td>Corrosion of second degree of neck, initial encounter</td>
</tr>
<tr>
<td>T20.67xD</td>
<td>Corrosion of second degree of neck, subsequent encounter</td>
</tr>
<tr>
<td>T20.67xS</td>
<td>Corrosion of second degree of neck, sequela</td>
</tr>
<tr>
<td>T20.69xA</td>
<td>Corrosion of second degree of multiple sites of head, face, and neck, initial encounter</td>
</tr>
<tr>
<td>T20.69xD</td>
<td>Corrosion of second degree of multiple sites of head, face, and neck, subsequent encounter</td>
</tr>
<tr>
<td>T20.69xS</td>
<td>Corrosion of second degree of multiple sites of head, face, and neck, sequela</td>
</tr>
<tr>
<td>T20.711A</td>
<td>Corrosion of third degree of right ear [any part, except ear drum], initial encounter</td>
</tr>
<tr>
<td>T20.711D</td>
<td>Corrosion of third degree of right ear [any part, except ear drum], subsequent encounter</td>
</tr>
<tr>
<td>T20.711S</td>
<td>Corrosion of third degree of right ear [any part, except ear drum], sequela</td>
</tr>
<tr>
<td>T20.712A</td>
<td>Corrosion of third degree of left ear [any part, except ear drum], initial encounter</td>
</tr>
<tr>
<td>T20.712D</td>
<td>Corrosion of third degree of left ear [any part, except ear drum], subsequent encounter</td>
</tr>
<tr>
<td>T20.712S</td>
<td>Corrosion of third degree of left ear [any part, except ear drum], sequela</td>
</tr>
</tbody>
</table>
T20.72xA  Corrosion of third degree of lip(s), initial encounter
T20.72xD  Corrosion of third degree of lip(s), subsequent encounter
T20.72xS  Corrosion of third degree of lip(s), sequela
T20.73xA  Corrosion of third degree of chin, initial encounter
T20.73xD  Corrosion of third degree of chin, subsequent encounter
T20.73xS  Corrosion of third degree of chin, sequela
T20.74xA  Corrosion of third degree of nose (septum), initial encounter
T20.74xD  Corrosion of third degree of nose (septum), subsequent encounter
T20.74xS  Corrosion of third degree of nose (septum), sequela
T20.75xA  Corrosion of third degree of scalp [any part], initial encounter
T20.75xD  Corrosion of third degree of scalp [any part], subsequent encounter
T20.75xS  Corrosion of third degree of scalp [any part], sequela
T20.76xA  Corrosion of third degree of forehead and cheek, initial encounter
T20.76xD  Corrosion of third degree of forehead and cheek, subsequent encounter
T20.76xS  Corrosion of third degree of forehead and cheek, sequela
T20.77xA  Corrosion of third degree of neck, initial encounter
T20.77xD  Corrosion of third degree of neck, subsequent encounter
T20.77xS  Corrosion of third degree of neck, sequela
T20.79xA  Corrosion of third degree of multiple sites of head, face, and neck, initial encounter
T20.79xD  Corrosion of third degree of multiple sites of head, face, and neck, subsequent encounter
T20.79xS  Corrosion of third degree of multiple sites of head, face, and neck, sequela
T21.21xA  Burn of second degree of chest wall, initial encounter
T21.21xD  Burn of second degree of chest wall, subsequent encounter
T21.21xS  Burn of second degree of chest wall, sequela
T21.22xA  Burn of second degree of abdominal wall, initial encounter
T21.22xD  Burn of second degree of abdominal wall, subsequent encounter
T21.22xS  Burn of second degree of abdominal wall, sequela
T21.23xA  Burn of second degree of upper back, initial encounter
T21.23xD  Burn of second degree of upper back, subsequent encounter
T21.23xS  Burn of second degree of upper back, sequela
T21.24xA  Burn of second degree of lower back, initial encounter
T21.24xD  Burn of second degree of lower back, subsequent encounter
T21.24xS  Burn of second degree of lower back, sequela
T21.25xA  Burn of second degree of buttock, initial encounter
T21.25xD  Burn of second degree of buttock, subsequent encounter
T21.25xS  Burn of second degree of buttock, sequela
T21.26xA  Burn of second degree of male genital region, initial encounter
T21.26xD  Burn of second degree of male genital region, subsequent encounter
T21.26xS  Burn of second degree of male genital region, sequela
T21.27xA  Burn of second degree of female genital region, initial encounter
T21.27xD  Burn of second degree of female genital region, subsequent encounter
T21.27xS  Burn of second degree of female genital region, sequela
T21.29xA  Burn of second degree of other site of trunk, initial encounter
T21.29xD  Burn of second degree of other site of trunk, subsequent encounter
T21.29xS  Burn of second degree of other site of trunk, sequela
T21.31xA  Burn of third degree of chest wall, initial encounter
T21.31xD  Burn of third degree of chest wall, subsequent encounter
T21.31xS  Burn of third degree of chest wall, sequela
T21.32xA  Burn of third degree of abdominal wall, initial encounter
T21.32xD  Burn of third degree of abdominal wall, subsequent encounter
T21.32xS  Burn of third degree of abdominal wall, sequela
T21.33xA  Burn of third degree of upper back, initial encounter
T21.33xD  Burn of third degree of upper back, subsequent encounter
T21.33xS  Burn of third degree of upper back, sequela

Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association
Contains Public Information
T21.34xA  Burn of third degree of lower back, initial encounter
T21.34xD  Burn of third degree of lower back, subsequent encounter
T21.34xS  Burn of third degree of lower back, sequela
T21.35xA  Burn of third degree of buttock, initial encounter
T21.35xD  Burn of third degree of buttock, subsequent encounter
T21.35xS  Burn of third degree of buttock, sequela
T21.36xA  Burn of third degree of male genital region, initial encounter
T21.36xD  Burn of third degree of male genital region, subsequent encounter
T21.36xS  Burn of third degree of male genital region, sequela
T21.37xA  Burn of third degree of female genital region, initial encounter
T21.37xD  Burn of third degree of female genital region, subsequent encounter
T21.37xS  Burn of third degree of female genital region, sequela
T21.39xA  Burn of third degree of other site of trunk, initial encounter
T21.39xD  Burn of third degree of other site of trunk, subsequent encounter
T21.39xS  Burn of third degree of other site of trunk, sequela
T21.61xA  Corrosion of second degree of chest wall, initial encounter
T21.61xD  Corrosion of second degree of chest wall, subsequent encounter
T21.61xS  Corrosion of second degree of chest wall, sequela
T21.62xA  Corrosion of second degree of abdominal wall, initial encounter
T21.62xD  Corrosion of second degree of abdominal wall, subsequent encounter
T21.62xS  Corrosion of second degree of abdominal wall, sequela
T21.63xA  Corrosion of second degree of upper back, initial encounter
T21.63xD  Corrosion of second degree of upper back, subsequent encounter
T21.63xS  Corrosion of second degree of upper back, sequela
T21.64xA  Corrosion of second degree of lower back, initial encounter
T21.64xD  Corrosion of second degree of lower back, subsequent encounter
T21.64xS  Corrosion of second degree of lower back, sequela
T21.65xA  Corrosion of second degree of buttock, initial encounter
T21.65xD  Corrosion of second degree of buttock, subsequent encounter
T21.65xS  Corrosion of second degree of buttock, sequela
T21.66xA  Corrosion of second degree of male genital region, initial encounter
T21.66xD  Corrosion of second degree of male genital region, subsequent encounter
T21.66xS  Corrosion of second degree of male genital region, sequela
T21.67xA  Corrosion of second degree of female genital region, initial encounter
T21.67xD  Corrosion of second degree of female genital region, subsequent encounter
T21.67xS  Corrosion of second degree of female genital region, sequela
T21.69xA  Corrosion of second degree of other site of trunk, initial encounter
T21.69xD  Corrosion of second degree of other site of trunk, subsequent encounter
T21.69xS  Corrosion of second degree of other site of trunk, sequela
T21.71xA  Corrosion of third degree of chest wall, initial encounter
T21.71xD  Corrosion of third degree of chest wall, subsequent encounter
T21.71xS  Corrosion of third degree of chest wall, sequela
T21.72xA  Corrosion of third degree of abdominal wall, initial encounter
T21.72xD  Corrosion of third degree of abdominal wall, subsequent encounter
T21.72xS  Corrosion of third degree of abdominal wall, sequela
T21.73xA  Corrosion of third degree of upper back, initial encounter
T21.73xD  Corrosion of third degree of upper back, subsequent encounter
T21.73xS  Corrosion of third degree of upper back, sequela
T21.74xA  Corrosion of third degree of lower back, initial encounter
T21.74xD  Corrosion of third degree of lower back, subsequent encounter
T21.74xS  Corrosion of third degree of lower back, sequela
T21.75xA  Corrosion of third degree of buttock, initial encounter
T21.75xD  Corrosion of third degree of buttock, subsequent encounter
T21.75xS  Corrosion of third degree of buttock, sequela
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T21.76xA</td>
<td>Corrosion of third degree of male genital region, initial encounter</td>
</tr>
<tr>
<td>T21.76xD</td>
<td>Corrosion of third degree of male genital region, subsequent encounter</td>
</tr>
<tr>
<td>T21.76xS</td>
<td>Corrosion of third degree of male genital region, sequela</td>
</tr>
<tr>
<td>T21.77xA</td>
<td>Corrosion of third degree of female genital region, initial encounter</td>
</tr>
<tr>
<td>T21.77xD</td>
<td>Corrosion of third degree of female genital region, subsequent encounter</td>
</tr>
<tr>
<td>T21.77xS</td>
<td>Corrosion of third degree of female genital region, sequela</td>
</tr>
<tr>
<td>T21.79xA</td>
<td>Corrosion of third degree of other site of trunk, initial encounter</td>
</tr>
<tr>
<td>T21.79xD</td>
<td>Corrosion of third degree of other site of trunk, subsequent encounter</td>
</tr>
<tr>
<td>T21.79xS</td>
<td>Corrosion of third degree of other site of trunk, sequela</td>
</tr>
<tr>
<td>T22.211A</td>
<td>Burn of second degree of right forearm, initial encounter</td>
</tr>
<tr>
<td>T22.211D</td>
<td>Burn of second degree of right forearm, subsequent encounter</td>
</tr>
<tr>
<td>T22.211S</td>
<td>Burn of second degree of right forearm, sequela</td>
</tr>
<tr>
<td>T22.212A</td>
<td>Burn of second degree of left forearm, initial encounter</td>
</tr>
<tr>
<td>T22.212D</td>
<td>Burn of second degree of left forearm, subsequent encounter</td>
</tr>
<tr>
<td>T22.212S</td>
<td>Burn of second degree of left forearm, sequela</td>
</tr>
<tr>
<td>T22.221A</td>
<td>Burn of second degree of right elbow, initial encounter</td>
</tr>
<tr>
<td>T22.221D</td>
<td>Burn of second degree of right elbow, subsequent encounter</td>
</tr>
<tr>
<td>T22.221S</td>
<td>Burn of second degree of right elbow, sequela</td>
</tr>
<tr>
<td>T22.222A</td>
<td>Burn of second degree of left elbow, initial encounter</td>
</tr>
<tr>
<td>T22.222D</td>
<td>Burn of second degree of left elbow, subsequent encounter</td>
</tr>
<tr>
<td>T22.222S</td>
<td>Burn of second degree of left elbow, sequela</td>
</tr>
<tr>
<td>T22.231A</td>
<td>Burn of second degree of right upper arm, initial encounter</td>
</tr>
<tr>
<td>T22.231D</td>
<td>Burn of second degree of right upper arm, subsequent encounter</td>
</tr>
<tr>
<td>T22.231S</td>
<td>Burn of second degree of right upper arm, sequela</td>
</tr>
<tr>
<td>T22.232A</td>
<td>Burn of second degree of left upper arm, initial encounter</td>
</tr>
<tr>
<td>T22.232D</td>
<td>Burn of second degree of left upper arm, subsequent encounter</td>
</tr>
<tr>
<td>T22.232S</td>
<td>Burn of second degree of left upper arm, sequela</td>
</tr>
<tr>
<td>T22.241A</td>
<td>Burn of second degree of right axilla, initial encounter</td>
</tr>
<tr>
<td>T22.241D</td>
<td>Burn of second degree of right axilla, subsequent encounter</td>
</tr>
<tr>
<td>T22.241S</td>
<td>Burn of second degree of right axilla, sequela</td>
</tr>
<tr>
<td>T22.242A</td>
<td>Burn of second degree of left axilla, initial encounter</td>
</tr>
<tr>
<td>T22.242D</td>
<td>Burn of second degree of left axilla, subsequent encounter</td>
</tr>
<tr>
<td>T22.242S</td>
<td>Burn of second degree of left axilla, sequela</td>
</tr>
<tr>
<td>T22.251A</td>
<td>Burn of second degree of right shoulder, initial encounter</td>
</tr>
<tr>
<td>T22.251D</td>
<td>Burn of second degree of right shoulder, subsequent encounter</td>
</tr>
<tr>
<td>T22.251S</td>
<td>Burn of second degree of right shoulder, sequela</td>
</tr>
<tr>
<td>T22.252A</td>
<td>Burn of second degree of left shoulder, initial encounter</td>
</tr>
<tr>
<td>T22.252D</td>
<td>Burn of second degree of left shoulder, subsequent encounter</td>
</tr>
<tr>
<td>T22.252S</td>
<td>Burn of second degree of left shoulder, sequela</td>
</tr>
<tr>
<td>T22.261A</td>
<td>Burn of second degree of right scapular region, initial encounter</td>
</tr>
<tr>
<td>T22.261D</td>
<td>Burn of second degree of right scapular region, subsequent encounter</td>
</tr>
<tr>
<td>T22.261S</td>
<td>Burn of second degree of right scapular region, sequela</td>
</tr>
<tr>
<td>T22.262A</td>
<td>Burn of second degree of left scapular region, initial encounter</td>
</tr>
<tr>
<td>T22.262D</td>
<td>Burn of second degree of left scapular region, subsequent encounter</td>
</tr>
<tr>
<td>T22.262S</td>
<td>Burn of second degree of left scapular region, sequela</td>
</tr>
<tr>
<td>T22.291A</td>
<td>Burn of second degree of multiple sites of right shoulder and upper limb, except wrist and hand, initial encounter</td>
</tr>
<tr>
<td>T22.291D</td>
<td>Burn of second degree of multiple sites of right shoulder and upper limb, except wrist and hand, subsequent encounter</td>
</tr>
<tr>
<td>T22.291S</td>
<td>Burn of second degree of multiple sites of right shoulder and upper limb, except wrist and hand, sequela</td>
</tr>
<tr>
<td>T22.292A</td>
<td>Burn of second degree of multiple sites of left shoulder and upper limb, except wrist and hand, initial encounter</td>
</tr>
</tbody>
</table>
T22.292D  Burn of second degree of multiple sites of left shoulder and upper limb, except wrist and hand, subsequent encounter
T22.292S  Burn of second degree of multiple sites of left shoulder and upper limb, except wrist and hand, sequel
T22.311A  Burn of third degree of right forearm, initial encounter
T22.311D  Burn of third degree of right forearm, subsequent encounter
T22.311S  Burn of third degree of right forearm, sequel
T22.312A  Burn of third degree of left forearm, initial encounter
T22.312D  Burn of third degree of left forearm, subsequent encounter
T22.312S  Burn of third degree of left forearm, sequel
T22.321A  Burn of third degree of right elbow, initial encounter
T22.321D  Burn of third degree of right elbow, subsequent encounter
T22.321S  Burn of third degree of right elbow, sequel
T22.322A  Burn of third degree of left elbow, initial encounter
T22.322D  Burn of third degree of left elbow, subsequent encounter
T22.322S  Burn of third degree of left elbow, sequel
T22.331A  Burn of third degree of right upper arm, initial encounter
T22.331D  Burn of third degree of right upper arm, subsequent encounter
T22.331S  Burn of third degree of right upper arm, sequel
T22.332A  Burn of third degree of left upper arm, initial encounter
T22.332D  Burn of third degree of left upper arm, subsequent encounter
T22.332S  Burn of third degree of left upper arm, sequel
T22.341A  Burn of third degree of right axilla, initial encounter
T22.341D  Burn of third degree of right axilla, subsequent encounter
T22.341S  Burn of third degree of right axilla, sequel
T22.342A  Burn of third degree of left axilla, initial encounter
T22.342D  Burn of third degree of left axilla, subsequent encounter
T22.342S  Burn of third degree of left axilla, sequel
T22.351A  Burn of third degree of right shoulder, initial encounter
T22.351D  Burn of third degree of right shoulder, subsequent encounter
T22.351S  Burn of third degree of right shoulder, sequel
T22.352A  Burn of third degree of left shoulder, initial encounter
T22.352D  Burn of third degree of left shoulder, subsequent encounter
T22.352S  Burn of third degree of left shoulder, sequel
T22.361A  Burn of third degree of right scapular region, initial encounter
T22.361D  Burn of third degree of right scapular region, subsequent encounter
T22.361S  Burn of third degree of right scapular region, sequel
T22.362A  Burn of third degree of left scapular region, initial encounter
T22.362D  Burn of third degree of left scapular region, subsequent encounter
T22.362S  Burn of third degree of left scapular region, sequel
T22.391A  Burn of third degree of multiple sites of right shoulder and upper limb, except wrist and hand, initial encounter
T22.391D  Burn of third degree of multiple sites of right shoulder and upper limb, except wrist and hand, subsequent encounter
T22.391S  Burn of third degree of multiple sites of right shoulder and upper limb, except wrist and hand, sequel
T22.392A  Burn of third degree of multiple sites of left shoulder and upper limb, except wrist and hand, initial encounter
T22.392D  Burn of third degree of multiple sites of left shoulder and upper limb, except wrist and hand, subsequent encounter
T22.392S  Burn of third degree of multiple sites of left shoulder and upper limb, except wrist and hand, sequel
T22.611A  Corrosion of second degree of right forearm, initial encounter
T22.611D  Corrosion of second degree of right forearm, subsequent encounter

Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T22.611S</td>
<td>Corrosion of second degree of right forearm, sequela</td>
</tr>
<tr>
<td>T22.612A</td>
<td>Corrosion of second degree of left forearm, initial encounter</td>
</tr>
<tr>
<td>T22.612D</td>
<td>Corrosion of second degree of left forearm, subsequent encounter</td>
</tr>
<tr>
<td>T22.612S</td>
<td>Corrosion of second degree of left forearm, sequela</td>
</tr>
<tr>
<td>T22.621A</td>
<td>Corrosion of second degree of right elbow, initial encounter</td>
</tr>
<tr>
<td>T22.621D</td>
<td>Corrosion of second degree of right elbow, subsequent encounter</td>
</tr>
<tr>
<td>T22.621S</td>
<td>Corrosion of second degree of right elbow, sequela</td>
</tr>
<tr>
<td>T22.622A</td>
<td>Corrosion of second degree of left elbow, initial encounter</td>
</tr>
<tr>
<td>T22.622D</td>
<td>Corrosion of second degree of left elbow, subsequent encounter</td>
</tr>
<tr>
<td>T22.622S</td>
<td>Corrosion of second degree of left elbow, sequela</td>
</tr>
<tr>
<td>T22.631A</td>
<td>Corrosion of second degree of right upper arm, initial encounter</td>
</tr>
<tr>
<td>T22.631D</td>
<td>Corrosion of second degree of right upper arm, subsequent encounter</td>
</tr>
<tr>
<td>T22.631S</td>
<td>Corrosion of second degree of right upper arm, sequela</td>
</tr>
<tr>
<td>T22.632A</td>
<td>Corrosion of second degree of left upper arm, initial encounter</td>
</tr>
<tr>
<td>T22.632D</td>
<td>Corrosion of second degree of left upper arm, subsequent encounter</td>
</tr>
<tr>
<td>T22.632S</td>
<td>Corrosion of second degree of left upper arm, sequela</td>
</tr>
<tr>
<td>T22.641A</td>
<td>Corrosion of second degree of right axilla, initial encounter</td>
</tr>
<tr>
<td>T22.641D</td>
<td>Corrosion of second degree of right axilla, subsequent encounter</td>
</tr>
<tr>
<td>T22.641S</td>
<td>Corrosion of second degree of right axilla, sequela</td>
</tr>
<tr>
<td>T22.642A</td>
<td>Corrosion of second degree of left axilla, initial encounter</td>
</tr>
<tr>
<td>T22.642D</td>
<td>Corrosion of second degree of left axilla, subsequent encounter</td>
</tr>
<tr>
<td>T22.642S</td>
<td>Corrosion of second degree of left axilla, sequela</td>
</tr>
<tr>
<td>T22.651A</td>
<td>Corrosion of second degree of right shoulder, initial encounter</td>
</tr>
<tr>
<td>T22.651D</td>
<td>Corrosion of second degree of right shoulder, subsequent encounter</td>
</tr>
<tr>
<td>T22.651S</td>
<td>Corrosion of second degree of right shoulder, sequela</td>
</tr>
<tr>
<td>T22.652A</td>
<td>Corrosion of second degree of left shoulder, initial encounter</td>
</tr>
<tr>
<td>T22.652D</td>
<td>Corrosion of second degree of left shoulder, subsequent encounter</td>
</tr>
<tr>
<td>T22.652S</td>
<td>Corrosion of second degree of left shoulder, sequela</td>
</tr>
<tr>
<td>T22.661A</td>
<td>Corrosion of second degree of right scapular region, initial encounter</td>
</tr>
<tr>
<td>T22.661D</td>
<td>Corrosion of second degree of right scapular region, subsequent encounter</td>
</tr>
<tr>
<td>T22.661S</td>
<td>Corrosion of second degree of right scapular region, sequela</td>
</tr>
<tr>
<td>T22.662A</td>
<td>Corrosion of second degree of left scapular region, initial encounter</td>
</tr>
<tr>
<td>T22.662D</td>
<td>Corrosion of second degree of left scapular region, subsequent encounter</td>
</tr>
<tr>
<td>T22.662S</td>
<td>Corrosion of second degree of left scapular region, sequela</td>
</tr>
<tr>
<td>T22.691A</td>
<td>Corrosion of second degree of multiple sites of right shoulder and upper limb, except wrist and hand, initial encounter</td>
</tr>
<tr>
<td>T22.691D</td>
<td>Corrosion of second degree of multiple sites of right shoulder and upper limb, except wrist and hand, subsequent encounter</td>
</tr>
<tr>
<td>T22.691S</td>
<td>Corrosion of second degree of multiple sites of right shoulder and upper limb, except wrist and hand, sequela</td>
</tr>
<tr>
<td>T22.692A</td>
<td>Corrosion of second degree of multiple sites of left shoulder and upper limb, except wrist and hand, initial encounter</td>
</tr>
<tr>
<td>T22.692D</td>
<td>Corrosion of second degree of multiple sites of left shoulder and upper limb, except wrist and hand, subsequent encounter</td>
</tr>
<tr>
<td>T22.692S</td>
<td>Corrosion of second degree of multiple sites of left shoulder and upper limb, except wrist and hand, sequela</td>
</tr>
<tr>
<td>T22.711A</td>
<td>Corrosion of third degree of right forearm, initial encounter</td>
</tr>
<tr>
<td>T22.711D</td>
<td>Corrosion of third degree of right forearm, subsequent encounter</td>
</tr>
<tr>
<td>T22.711S</td>
<td>Corrosion of third degree of right forearm, sequela</td>
</tr>
<tr>
<td>T22.712A</td>
<td>Corrosion of third degree of left forearm, initial encounter</td>
</tr>
<tr>
<td>T22.712D</td>
<td>Corrosion of third degree of left forearm, subsequent encounter</td>
</tr>
<tr>
<td>T22.712S</td>
<td>Corrosion of third degree of left forearm, sequela</td>
</tr>
<tr>
<td>T22.721A</td>
<td>Corrosion of third degree of right elbow, initial encounter</td>
</tr>
<tr>
<td>T22.721D</td>
<td>Corrosion of third degree of right elbow, subsequent encounter</td>
</tr>
</tbody>
</table>


Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information
T22.721S  Corrosion of third degree of right elbow, sequela
T22.722A  Corrosion of third degree of left elbow, initial encounter
T22.722D  Corrosion of third degree of left elbow, subsequent encounter
T22.722S  Corrosion of third degree of left elbow, sequela
T22.731A  Corrosion of third degree of right upper arm, initial encounter
T22.731D  Corrosion of third degree of right upper arm, subsequent encounter
T22.731S  Corrosion of third degree of right upper arm, sequela
T22.732A  Corrosion of third degree of left upper arm, initial encounter
T22.732D  Corrosion of third degree of left upper arm, subsequent encounter
T22.732S  Corrosion of third degree of left upper arm, sequela
T22.741A  Corrosion of third degree of right axilla, initial encounter
T22.741D  Corrosion of third degree of right axilla, subsequent encounter
T22.741S  Corrosion of third degree of right axilla, sequela
T22.742A  Corrosion of third degree of left axilla, initial encounter
T22.742D  Corrosion of third degree of left axilla, subsequent encounter
T22.742S  Corrosion of third degree of left axilla, sequela
T22.751A  Corrosion of third degree of right shoulder, initial encounter
T22.751D  Corrosion of third degree of right shoulder, subsequent encounter
T22.751S  Corrosion of third degree of right shoulder, sequela
T22.752A  Corrosion of third degree of left shoulder, initial encounter
T22.752D  Corrosion of third degree of left shoulder, subsequent encounter
T22.752S  Corrosion of third degree of left shoulder, sequela
T22.761A  Corrosion of third degree of right scapular region, initial encounter
T22.761D  Corrosion of third degree of right scapular region, subsequent encounter
T22.761S  Corrosion of third degree of right scapular region, sequela
T22.762A  Corrosion of third degree of left scapular region, initial encounter
T22.762D  Corrosion of third degree of left scapular region, subsequent encounter
T22.762S  Corrosion of third degree of left scapular region, sequela
T22.791A  Corrosion of third degree of multiple sites of right shoulder and upper limb, except wrist and hand, initial encounter
T22.791D  Corrosion of third degree of multiple sites of right shoulder and upper limb, except wrist and hand, subsequent encounter
T22.791S  Corrosion of third degree of multiple sites of right shoulder and upper limb, except wrist and hand, sequela
T22.792A  Corrosion of third degree of multiple sites of left shoulder and upper limb, except wrist and hand, initial encounter
T22.792D  Corrosion of third degree of multiple sites of left shoulder and upper limb, except wrist and hand, subsequent encounter
T22.792S  Corrosion of third degree of multiple sites of left shoulder and upper limb, except wrist and hand, sequela
T23.211A  Burn of second degree of right thumb (nail), initial encounter
T23.211D  Burn of second degree of right thumb (nail), subsequent encounter
T23.211S  Burn of second degree of right thumb (nail), sequela
T23.212A  Burn of second degree of left thumb (nail), initial encounter
T23.212D  Burn of second degree of left thumb (nail), subsequent encounter
T23.212S  Burn of second degree of left thumb (nail), sequela
T23.221A  Burn of second degree of single right finger (nail) except thumb, initial encounter
T23.221D  Burn of second degree of single right finger (nail) except thumb, subsequent encounter
T23.221S  Burn of second degree of single right finger (nail) except thumb, sequela
T23.222A  Burn of second degree of single left finger (nail) except thumb, initial encounter
T23.222D  Burn of second degree of single left finger (nail) except thumb, subsequent encounter
T23.222S  Burn of second degree of single left finger (nail) except thumb, sequela
T23.231A  Burn of second degree of multiple right fingers (nail), not including thumb, initial encounter
T23.231D  Burn of second degree of multiple right fingers (nail), not including thumb, subsequent encounter
T23.231S  Burn of second degree of multiple right fingers (nail), not including thumb, sequela
T23.232A  Burn of second degree of multiple left fingers (nail), not including thumb, initial encounter
T23.232D  Burn of second degree of multiple left fingers (nail), not including thumb, subsequent encounter
T23.232S  Burn of second degree of multiple left fingers (nail), not including thumb, sequela
T23.241A  Burn of second degree of multiple right fingers (nail), including thumb, initial encounter
T23.241D  Burn of second degree of multiple right fingers (nail), including thumb, subsequent encounter
T23.242A  Burn of second degree of multiple left fingers (nail), including thumb, initial encounter
T23.242D  Burn of second degree of multiple left fingers (nail), including thumb, subsequent encounter
T23.242S  Burn of second degree of multiple left fingers (nail), including thumb, sequela
T23.251A  Burn of second degree of right palm, initial encounter
T23.251D  Burn of second degree of right palm, subsequent encounter
T23.251S  Burn of second degree of right palm, sequela
T23.252A  Burn of second degree of left palm, initial encounter
T23.252D  Burn of second degree of left palm, subsequent encounter
T23.252S  Burn of second degree of left palm, sequela
T23.261A  Burn of second degree of back of right hand, initial encounter
T23.261D  Burn of second degree of back of right hand, subsequent encounter
T23.261S  Burn of second degree of back of right hand, sequela
T23.262A  Burn of second degree of back of left hand, initial encounter
T23.262D  Burn of second degree of back of left hand, subsequent encounter
T23.262S  Burn of second degree of back of left hand, sequela
T23.271A  Burn of second degree of right wrist, initial encounter
T23.271D  Burn of second degree of right wrist, subsequent encounter
T23.271S  Burn of second degree of right wrist, sequela
T23.272A  Burn of second degree of left wrist, initial encounter
T23.272D  Burn of second degree of left wrist, subsequent encounter
T23.272S  Burn of second degree of left wrist, sequela
T23.291A  Burn of second degree of multiple sites of right wrist and hand, initial encounter
T23.291D  Burn of second degree of multiple sites of right wrist and hand, subsequent encounter
T23.291S  Burn of second degree of multiple sites of right wrist and hand, sequela
T23.292A  Burn of second degree of multiple sites of left wrist and hand, initial encounter
T23.292D  Burn of second degree of multiple sites of left wrist and hand, subsequent encounter
T23.292S  Burn of second degree of multiple sites of left wrist and hand, sequela
T23.311A  Burn of third degree of right thumb (nail), initial encounter
T23.311D  Burn of third degree of right thumb (nail), subsequent encounter
T23.311S  Burn of third degree of right thumb (nail), sequela
T23.312A  Burn of third degree of left thumb (nail), initial encounter
T23.312D  Burn of third degree of left thumb (nail), subsequent encounter
T23.312S  Burn of third degree of left thumb (nail), sequela
T23.321A  Burn of third degree of single right finger (nail) except thumb, initial encounter
T23.321D  Burn of third degree of single right finger (nail) except thumb, subsequent encounter
T23.321S  Burn of third degree of single right finger (nail) except thumb, sequela
T23.322A  Burn of third degree of single left finger (nail) except thumb, initial encounter
T23.322D  Burn of third degree of single left finger (nail) except thumb, subsequent encounter
T23.322S  Burn of third degree of single left finger (nail) except thumb, sequela
T23.331A  Burn of third degree of multiple right fingers (nail), not including thumb, initial encounter
T23.331D  Burn of third degree of multiple right fingers (nail), not including thumb, subsequent encounter
T23.331S  Burn of third degree of multiple right fingers (nail), not including thumb, sequela
T23.332A  Burn of third degree of multiple left fingers (nail), not including thumb, initial encounter
T23.332D  Burn of third degree of multiple left fingers (nail), not including thumb, subsequent encounter
T23.332S  Burn of third degree of multiple left fingers (nail), not including thumb, sequela
T23.332S Burn of third degree of multiple left fingers (nail), not including thumb, sequela
T23.341A Burn of third degree of multiple right fingers (nail), including thumb, initial encounter
T23.341D Burn of third degree of multiple right fingers (nail), including thumb, subsequent encounter
T23.341S Burn of third degree of multiple right fingers (nail), including thumb, sequela
T23.342A Burn of third degree of multiple left fingers (nail), including thumb, initial encounter
T23.342D Burn of third degree of multiple left fingers (nail), including thumb, subsequent encounter
T23.342S Burn of third degree of multiple left fingers (nail), including thumb, sequela
T23.351A Burn of third degree of right palm, initial encounter
T23.351D Burn of third degree of right palm, subsequent encounter
T23.351S Burn of third degree of right palm, sequela
T23.352A Burn of third degree of left palm, initial encounter
T23.352D Burn of third degree of left palm, subsequent encounter
T23.352S Burn of third degree of left palm, sequela
T23.361A Burn of third degree of back of right hand, initial encounter
T23.361D Burn of third degree of back of right hand, subsequent encounter
T23.361S Burn of third degree of back of right hand, sequela
T23.362A Burn of third degree of back of left hand, initial encounter
T23.362D Burn of third degree of back of left hand, subsequent encounter
T23.362S Burn of third degree of back of left hand, sequela
T23.371A Burn of third degree of right wrist, initial encounter
T23.371D Burn of third degree of right wrist, subsequent encounter
T23.371S Burn of third degree of right wrist, sequela
T23.372A Burn of third degree of left wrist, initial encounter
T23.372D Burn of third degree of left wrist, subsequent encounter
T23.372S Burn of third degree of left wrist, sequela
T23.391A Burn of third degree of multiple sites of right wrist and hand, initial encounter
T23.391D Burn of third degree of multiple sites of right wrist and hand, subsequent encounter
T23.391S Burn of third degree of multiple sites of right wrist and hand, sequela
T23.392A Burn of third degree of multiple sites of left wrist and hand, initial encounter
T23.392D Burn of third degree of multiple sites of left wrist and hand, subsequent encounter
T23.392S Burn of third degree of multiple sites of left wrist and hand, sequela
T23.611A Corrosion of second degree of right thumb (nail), initial encounter
T23.611D Corrosion of second degree of right thumb (nail), subsequent encounter
T23.611S Corrosion of second degree of right thumb (nail), sequela
T23.612A Corrosion of second degree of left thumb (nail), initial encounter
T23.612D Corrosion of second degree of left thumb (nail), subsequent encounter
T23.612S Corrosion of second degree of left thumb (nail), sequela
T23.621A Corrosion of second degree of single right finger (nail) except thumb, initial encounter
T23.621D Corrosion of second degree of single right finger (nail) except thumb, subsequent encounter
T23.621S Corrosion of second degree of single right finger (nail) except thumb, sequela
T23.622A Corrosion of second degree of single left finger (nail) except thumb, initial encounter
T23.622D Corrosion of second degree of single left finger (nail) except thumb, subsequent encounter
T23.622S Corrosion of second degree of single left finger (nail) except thumb, sequela
T23.631A Corrosion of second degree of multiple right fingers (nail), not including thumb, initial encounter
T23.631D Corrosion of second degree of multiple right fingers (nail), not including thumb, subsequent encounter
T23.631S Corrosion of second degree of multiple right fingers (nail), not including thumb, sequela
T23.632A Corrosion of second degree of multiple left fingers (nail), not including thumb, initial encounter
T23.632D Corrosion of second degree of multiple left fingers (nail), not including thumb, subsequent encounter
T23.632S Corrosion of second degree of multiple left fingers (nail), not including thumb, sequela
T23.641A Corrosion of second degree of multiple right fingers (nail), including thumb, initial encounter
T23.641D  Corrosion of second degree of multiple right fingers (nail), including thumb, subsequent encounter
T23.641S  Corrosion of second degree of multiple right fingers (nail), including thumb, sequela
T23.642A  Corrosion of second degree of multiple left fingers (nail), including thumb, initial encounter
T23.642D  Corrosion of second degree of multiple left fingers (nail), including thumb, subsequent encounter
T23.642S  Corrosion of second degree of multiple left fingers (nail), including thumb, sequela
T23.651A  Corrosion of second degree of right palm, initial encounter
T23.651D  Corrosion of second degree of right palm, subsequent encounter
T23.651S  Corrosion of second degree of right palm, sequela
T23.652A  Corrosion of second degree of left palm, initial encounter
T23.652D  Corrosion of second degree of left palm, subsequent encounter
T23.652S  Corrosion of second degree of left palm, sequela
T23.661A  Corrosion of second degree back of right hand, initial encounter
T23.661D  Corrosion of second degree back of right hand, subsequent encounter
T23.661S  Corrosion of second degree back of right hand, sequela
T23.662A  Corrosion of second degree back of left hand, initial encounter
T23.662D  Corrosion of second degree back of left hand, subsequent encounter
T23.662S  Corrosion of second degree back of left hand, sequela
T23.671A  Corrosion of third degree of right thumb (nail), initial encounter
T23.671D  Corrosion of third degree of right thumb (nail), subsequent encounter
T23.671S  Corrosion of third degree of right thumb (nail), sequela
T23.672A  Corrosion of third degree of single right finger (nail) except thumb, initial encounter
T23.672D  Corrosion of third degree of single right finger (nail) except thumb, subsequent encounter
T23.672S  Corrosion of third degree of single right finger (nail) except thumb, sequela
T23.691A  Corrosion of second degree of multiple sites of right wrist and hand, initial encounter
T23.691D  Corrosion of second degree of multiple sites of right wrist and hand, subsequent encounter
T23.691S  Corrosion of second degree of multiple sites of right wrist and hand, sequela
T23.692A  Corrosion of second degree of multiple sites of left wrist and hand, initial encounter
T23.692D  Corrosion of second degree of multiple sites of left wrist and hand, subsequent encounter
T23.692S  Corrosion of second degree of multiple sites of left wrist and hand, sequela
T23.711A  Corrosion of third degree of right thumb (nail), initial encounter
T23.711D  Corrosion of third degree of right thumb (nail), subsequent encounter
T23.711S  Corrosion of third degree of right thumb (nail), sequela
T23.712A  Corrosion of third degree of single left finger (nail) except thumb, initial encounter
T23.712D  Corrosion of third degree of single left finger (nail) except thumb, subsequent encounter
T23.712S  Corrosion of third degree of single left finger (nail) except thumb, sequela
T23.731A  Corrosion of third degree of multiple right fingers (nail), not including thumb, initial encounter
T23.731D  Corrosion of third degree of multiple right fingers (nail), not including thumb, subsequent encounter
T23.731S  Corrosion of third degree of multiple right fingers (nail), not including thumb, sequela
T23.732A  Corrosion of third degree of multiple left fingers (nail), not including thumb, initial encounter
T23.732D  Corrosion of third degree of multiple left fingers (nail), not including thumb, subsequent encounter
T23.732S  Corrosion of third degree of multiple left fingers (nail), not including thumb, sequela
T23.741A  Corrosion of third degree of multiple right fingers (nail), including thumb, initial encounter
T23.741D  Corrosion of third degree of multiple right fingers (nail), including thumb, subsequent encounter
T23.741S  Corrosion of third degree of multiple right fingers (nail), including thumb, sequela

Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association
Contains Public Information
T23.741S  Corrosion of third degree of multiple right fingers (nail), including thumb, sequela
T23.742A  Corrosion of third degree of multiple left fingers (nail), including thumb, initial encounter
T23.742D  Corrosion of third degree of multiple left fingers (nail), including thumb, subsequent encounter
T23.742S  Corrosion of third degree of multiple left fingers (nail), including thumb, sequela
T23.751A  Corrosion of third degree of right palm, initial encounter
T23.751D  Corrosion of third degree of right palm, subsequent encounter
T23.752A  Corrosion of third degree of left palm, initial encounter
T23.752D  Corrosion of third degree of left palm, subsequent encounter
T23.752S  Corrosion of third degree of left palm, sequela
T23.761A  Corrosion of third degree of back of right hand, initial encounter
T23.761D  Corrosion of third degree of back of right hand, subsequent encounter
T23.761S  Corrosion of third degree of back of right hand, sequela
T23.762A  Corrosion of third degree of back of left hand, initial encounter
T23.762D  Corrosion of third degree of back of left hand, subsequent encounter
T23.762S  Corrosion of third degree of back of left hand, sequela
T23.771A  Corrosion of third degree of right wrist, initial encounter
T23.771D  Corrosion of third degree of right wrist, subsequent encounter
T23.771S  Corrosion of third degree of right wrist, sequela
T23.772A  Corrosion of third degree of left wrist, initial encounter
T23.772D  Corrosion of third degree of left wrist, subsequent encounter
T23.772S  Corrosion of third degree of left wrist, sequela
T23.791A  Corrosion of third degree of multiple sites of right wrist and hand, initial encounter
T23.791D  Corrosion of third degree of multiple sites of right wrist and hand, subsequent encounter
T23.791S  Corrosion of third degree of multiple sites of right wrist and hand, sequela
T23.792A  Corrosion of third degree of multiple sites of left wrist and hand, initial encounter
T23.792D  Corrosion of third degree of multiple sites of left wrist and hand, subsequent encounter
T23.792S  Corrosion of third degree of multiple sites of left wrist and hand, sequela
T24.211A  Burn of second degree of right thigh, initial encounter
T24.211D  Burn of second degree of right thigh, subsequent encounter
T24.211S  Burn of second degree of right thigh, sequela
T24.212A  Burn of second degree of left thigh, initial encounter
T24.212D  Burn of second degree of left thigh, subsequent encounter
T24.212S  Burn of second degree of left thigh, sequela
T24.221A  Burn of second degree of right knee, initial encounter
T24.221D  Burn of second degree of right knee, subsequent encounter
T24.221S  Burn of second degree of right knee, sequela
T24.222A  Burn of second degree of left knee, initial encounter
T24.222D  Burn of second degree of left knee, subsequent encounter
T24.222S  Burn of second degree of left knee, sequela
T24.231A  Burn of second degree of right lower leg, initial encounter
T24.231D  Burn of second degree of right lower leg, subsequent encounter
T24.231S  Burn of second degree of right lower leg, sequela
T24.232A  Burn of second degree of left lower leg, initial encounter
T24.232D  Burn of second degree of left lower leg, subsequent encounter
T24.232S  Burn of second degree of left lower leg, sequela
T24.291A  Burn of second degree of multiple sites of right lower limb, except ankle and foot, initial encounter
T24.291D  Burn of second degree of multiple sites of right lower limb, except ankle and foot, subsequent encounter
T24.291S  Burn of second degree of multiple sites of right lower limb, except ankle and foot, sequela
T24.292A  Burn of second degree of multiple sites of left lower limb, except ankle and foot, initial encounter
T24.292D  Burn of second degree of multiple sites of left lower limb, except ankle and foot, subsequent encounter
T24.292S  Burn of second degree of multiple sites of left lower limb, except ankle and foot, sequela
T24.311A  Burn of third degree of right thigh, initial encounter
T24.311D  Burn of third degree of right thigh, subsequent encounter
T24.311S  Burn of third degree of right thigh, sequela
T24.312A  Burn of third degree of left thigh, initial encounter
T24.312D  Burn of third degree of left thigh, subsequent encounter
T24.312S  Burn of third degree of left thigh, sequela
T24.321A  Burn of third degree of right knee, initial encounter
T24.321D  Burn of third degree of right knee, subsequent encounter
T24.321S  Burn of third degree of right knee, sequela
T24.322A  Burn of third degree of left knee, initial encounter
T24.322D  Burn of third degree of left knee, subsequent encounter
T24.322S  Burn of third degree of left knee, sequela
T24.331A  Burn of third degree of right lower leg, initial encounter
T24.331D  Burn of third degree of right lower leg, subsequent encounter
T24.331S  Burn of third degree of right lower leg, sequela
T24.332A  Burn of third degree of left lower leg, initial encounter
T24.332D  Burn of third degree of left lower leg, subsequent encounter
T24.332S  Burn of third degree of left lower leg, sequela
T24.391A  Burn of third degree of multiple sites of right lower limb, except ankle and foot, initial encounter
T24.391D  Burn of third degree of multiple sites of right lower limb, except ankle and foot, subsequent encounter
T24.391S  Burn of third degree of multiple sites of right lower limb, except ankle and foot, sequela
T24.392A  Burn of third degree of multiple sites of left lower limb, except ankle and foot, initial encounter
T24.392D  Burn of third degree of multiple sites of left lower limb, except ankle and foot, subsequent encounter
T24.611A  Corrosion of second degree of right thigh, initial encounter
T24.611D  Corrosion of second degree of right thigh, subsequent encounter
T24.611S  Corrosion of second degree of right thigh, sequela
T24.612A  Corrosion of second degree of left thigh, initial encounter
T24.612D  Corrosion of second degree of left thigh, subsequent encounter
T24.612S  Corrosion of second degree of left thigh, sequela
T24.621A  Corrosion of second degree of right knee, initial encounter
T24.621D  Corrosion of second degree of right knee, subsequent encounter
T24.621S  Corrosion of second degree of right knee, sequela
T24.622A  Corrosion of second degree of left knee, initial encounter
T24.622D  Corrosion of second degree of left knee, subsequent encounter
T24.622S  Corrosion of second degree of left knee, sequela
T24.631A  Corrosion of second degree of right lower leg, initial encounter
T24.631D  Corrosion of second degree of right lower leg, subsequent encounter
T24.631S  Corrosion of second degree of right lower leg, sequela
T24.632A  Corrosion of second degree of left lower leg, initial encounter
T24.632D  Corrosion of second degree of left lower leg, subsequent encounter
T24.632S  Corrosion of second degree of left lower leg, sequela
T24.691A  Corrosion of second degree of multiple sites of right lower limb, except ankle and foot, initial encounter
T24.691D  Corrosion of second degree of multiple sites of right lower limb, except ankle and foot, subsequent encounter
T24.691S  Corrosion of second degree of multiple sites of right lower limb, except ankle and foot, sequela
T24.692A  Corrosion of second degree of multiple sites of left lower limb, except ankle and foot, initial encounter
T24.692D  Corrosion of second degree of multiple sites of left lower limb, except ankle and foot, subsequent encounter
T24.692S  Corrosion of second degree of multiple sites of left lower limb, except ankle and foot, sequela
T24.711A  Corrosion of third degree of right thigh, initial encounter
T24.711D  Corrosion of third degree of right thigh, subsequent encounter
T24.711S  Corrosion of third degree of right thigh, sequela
T24.712A  Corrosion of third degree of left thigh, initial encounter
T24.712D  Corrosion of third degree of left thigh, subsequent encounter
T24.712S  Corrosion of third degree of left thigh, sequela
T24.721A  Corrosion of third degree of right knee, initial encounter
T24.721D  Corrosion of third degree of right knee, subsequent encounter
T24.721S  Corrosion of third degree of right knee, sequela
T24.722A  Corrosion of third degree of left knee, initial encounter
T24.722D  Corrosion of third degree of left knee, subsequent encounter
T24.722S  Corrosion of third degree of left knee, sequela
T24.731A  Corrosion of third degree of right lower leg, initial encounter
T24.731D  Corrosion of third degree of right lower leg, subsequent encounter
T24.731S  Corrosion of third degree of right lower leg, sequela
T24.732A  Corrosion of third degree of left lower leg, initial encounter
T24.732D  Corrosion of third degree of left lower leg, subsequent encounter
T24.732S  Corrosion of third degree of left lower leg, sequela
T24.791A  Corrosion of third degree of multiple sites of right lower limb, except ankle and foot, initial encounter
T24.791D  Corrosion of third degree of multiple sites of right lower limb, except ankle and foot, subsequent encounter
T24.791S  Corrosion of third degree of multiple sites of right lower limb, except ankle and foot, sequela
T25.211A  Burn of second degree of right ankle, initial encounter
T25.211D  Burn of second degree of right ankle, subsequent encounter
T25.211S  Burn of second degree of right ankle, sequela
T25.212A  Burn of second degree of left ankle, initial encounter
T25.212D  Burn of second degree of left ankle, subsequent encounter
T25.212S  Burn of second degree of left ankle, sequela
T25.221A  Burn of second degree of right foot, initial encounter
T25.221D  Burn of second degree of right foot, subsequent encounter
T25.221S  Burn of second degree of right foot, sequela
T25.222A  Burn of second degree of left foot, initial encounter
T25.222D  Burn of second degree of left foot, subsequent encounter
T25.222S  Burn of second degree of left foot, sequela
T25.231A  Burn of second degree of right toe(s) (nail), initial encounter
T25.231D  Burn of second degree of right toe(s) (nail), subsequent encounter
T25.231S  Burn of second degree of right toe(s) (nail), sequela
T25.232A  Burn of second degree of left toe(s) (nail), initial encounter
T25.232D  Burn of second degree of left toe(s) (nail), subsequent encounter
T25.232S  Burn of second degree of left toe(s) (nail), sequela
T25.291A  Burn of second degree of multiple sites of right ankle and foot, initial encounter
T25.291D  Burn of second degree of multiple sites of right ankle and foot, subsequent encounter
T25.291S  Burn of second degree of multiple sites of right ankle and foot, sequela
T25.292A  Burn of second degree of multiple sites of left ankle and foot, initial encounter
T25.292D  Burn of second degree of multiple sites of left ankle and foot, subsequent encounter
T25.292S  Burn of second degree of multiple sites of left ankle and foot, sequela
T25.311A  Burn of third degree of right ankle, initial encounter
T25.311D  Burn of third degree of right ankle, subsequent encounter
T25.311S  Burn of third degree of right ankle, sequela
T25.312A  Burn of third degree of left ankle, initial encounter
T25.312D  Burn of third degree of left ankle, subsequent encounter
T25.312S  Burn of third degree of left ankle, sequela
T25.321A  Burn of third degree of right foot, initial encounter
T25.321D  Burn of third degree of right foot, subsequent encounter
T25.321S  Burn of third degree of right foot, sequela
T25.322A  Burn of third degree of left foot, initial encounter
T25.322D  Burn of third degree of left foot, subsequent encounter
T25.322S  Burn of third degree of left foot, sequela
T25.331A  Burn of third degree of right toe(s) (nail), initial encounter
T25.331D  Burn of third degree of right toe(s) (nail), subsequent encounter
T25.331S  Burn of third degree of right toe(s) (nail), sequela
T25.332A  Burn of third degree of left toe(s) (nail), initial encounter
T25.332D  Burn of third degree of left toe(s) (nail), subsequent encounter
T25.332S  Burn of third degree of left toe(s) (nail), sequela
T25.391A  Burn of third degree of multiple sites of right ankle and foot, initial encounter
T25.391D  Burn of third degree of multiple sites of right ankle and foot, subsequent encounter
T25.391S  Burn of third degree of multiple sites of right ankle and foot, sequela
T25.392A  Burn of third degree of multiple sites of left ankle and foot, initial encounter
T25.392D  Burn of third degree of multiple sites of left ankle and foot, subsequent encounter
T25.392S  Burn of third degree of multiple sites of left ankle and foot, sequela
T25.611A  Corrosion of second degree of right ankle, initial encounter
T25.611D  Corrosion of second degree of right ankle, subsequent encounter
T25.611S  Corrosion of second degree of right ankle, sequela
T25.612A  Corrosion of second degree of left ankle, initial encounter
T25.612D  Corrosion of second degree of left ankle, subsequent encounter
T25.612S  Corrosion of second degree of left ankle, sequela
T25.621A  Corrosion of second degree of right foot, initial encounter
T25.621D  Corrosion of second degree of right foot, subsequent encounter
T25.621S  Corrosion of second degree of right foot, sequela
T25.622A  Corrosion of second degree of left foot, initial encounter
T25.622D  Corrosion of second degree of left foot, subsequent encounter
T25.622S  Corrosion of second degree of left foot, sequela
T25.631A  Corrosion of second degree of right toe(s) (nail), initial encounter
T25.631D  Corrosion of second degree of right toe(s) (nail), subsequent encounter
T25.631S  Corrosion of second degree of right toe(s) (nail), sequela
T25.632A  Corrosion of second degree of left toe(s) (nail), initial encounter
T25.632D  Corrosion of second degree of left toe(s) (nail), subsequent encounter
T25.632S  Corrosion of second degree of left toe(s) (nail), sequela
T25.691A  Corrosion of second degree of right ankle and foot, initial encounter
T25.691D  Corrosion of second degree of right ankle and foot, subsequent encounter
T25.691S  Corrosion of second degree of right ankle and foot, sequela
T25.692A  Corrosion of second degree of left ankle and foot, initial encounter
T25.692D  Corrosion of second degree of left ankle and foot, subsequent encounter
T25.692S  Corrosion of second degree of left ankle and foot, sequela
T25.711A  Corrosion of third degree of right ankle, initial encounter
T25.711D  Corrosion of third degree of right ankle, subsequent encounter
T25.711S  Corrosion of third degree of right ankle, sequela
Bio-Engineered Skin and Soft Tissue Substitutes

T25.712A Corrosion of third degree of left ankle, initial encounter
T25.712D Corrosion of third degree of left ankle, subsequent encounter
T25.712S Corrosion of third degree of left ankle, sequela
T25.721A Corrosion of third degree of right foot, initial encounter
T25.721D Corrosion of third degree of right foot, subsequent encounter
T25.721S Corrosion of third degree of right foot, sequela
T25.722A Corrosion of third degree of left foot, initial encounter
T25.722D Corrosion of third degree of left foot, subsequent encounter
T25.722S Corrosion of third degree of left foot, sequela
T25.731A Corrosion of third degree of right toe(s) (nail), initial encounter
T25.731D Corrosion of third degree of right toe(s) (nail), subsequent encounter
T25.731S Corrosion of third degree of right toe(s) (nail), sequela
T25.732A Corrosion of third degree of left toe(s) (nail), initial encounter
T25.732D Corrosion of third degree of left toe(s) (nail), subsequent encounter
T25.732S Corrosion of third degree of left toe(s) (nail), sequela
T25.791A Corrosion of third degree of multiple sites of right ankle and foot, initial encounter
T25.791D Corrosion of third degree of multiple sites of right ankle and foot, subsequent encounter
T25.791S Corrosion of third degree of multiple sites of right ankle and foot, sequela
T25.792A Corrosion of third degree of multiple sites of left ankle and foot, initial encounter
T25.792D Corrosion of third degree of multiple sites of left ankle and foot, subsequent encounter
T25.792S Corrosion of third degree of multiple sites of left ankle and foot, sequela
T26.71xA Corrosion with resulting rupture and destruction of right eyeball, initial encounter
T26.71xD Corrosion with resulting rupture and destruction of right eyeball, subsequent encounter
T26.71xS Corrosion with resulting rupture and destruction of right eyeball, sequela
T26.72xA Corrosion with resulting rupture and destruction of left eyeball, initial encounter
T26.72xD Corrosion with resulting rupture and destruction of left eyeball, subsequent encounter
T26.72xS Corrosion with resulting rupture and destruction of left eyeball, sequela
T31.0 Burns involving less than 10% of body surface
T31.10 Burns involving 10-19% of body surface with 0% to 9% third degree burns
T31.11 Burns involving 10-19% of body surface with 0-19% third degree burns
T31.20 Burns involving 20-29% of body surface with 0% to 9% third degree burns
T31.21 Burns involving 20-29% of body surface with 10-19% third degree burns
T31.30 Burns involving 30-39% of body surface with 0% to 9% third degree burns
T31.31 Burns involving 30-39% of body surface with 10-19% third degree burns
T31.32 Burns involving 30-39% of body surface with 20-29% third degree burns
T31.40 Burns involving 40-49% of body surface with 0% to 9% third degree burns
T31.41 Burns involving 40-49% of body surface with 10-19% third degree burns
T31.42 Burns involving 40-49% of body surface with 20-29% third degree burns
T31.43 Burns involving 40-49% of body surface with 30-39% third degree burns
T31.44 Burns involving 40-49% of body surface with 40-49% third degree burns
T31.50 Burns involving 50-59% of body surface with 0% to 9% third degree burns
T31.51 Burns involving 50-59% of body surface with 10-19% third degree burns
T31.52 Burns involving 50-59% of body surface with 20-29% third degree burns
T31.53 Burns involving 50-59% of body surface with 30-39% third degree burns
T31.54 Burns involving 50-59% of body surface with 40-49% third degree burns
T31.55 Burns involving 50-59% of body surface with 50-59% third degree burns
T31.60 Burns involving 60-69% of body surface with 0% to 9% third degree burns
T31.61 Burns involving 60-69% of body surface with 10-19% third degree burns
T31.62 Burns involving 60-69% of body surface with 20-29% third degree burns
T31.63 Burns involving 60-69% of body surface with 30-39% third degree burns
T31.64 Burns involving 60-69% of body surface with 40-49% third degree burns
T31.65 Burns involving 60-69% of body surface with 50-59% third degree burns

Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information
T31.66  Burns involving 60-69% of body surface with 60-69% third degree burns
T31.70  Burns involving 70-79% of body surface with 0% to 9% third degree burns
T31.71  Burns involving 70-79% of body surface with 10-19% third degree burns
T31.72  Burns involving 70-79% of body surface with 20-29% third degree burns
T31.73  Burns involving 70-79% of body surface with 30-39% third degree burns
T31.74  Burns involving 70-79% of body surface with 40-49% third degree burns
T31.75  Burns involving 70-79% of body surface with 50-59% third degree burns
T31.76  Burns involving 70-79% of body surface with 60-69% third degree burns
T31.77  Burns involving 70-79% of body surface with 70-79% third degree burns
T31.80  Burns involving 80-89% of body surface with 0% to 9% third degree burns
T31.81  Burns involving 80-89% of body surface with 10-19% third degree burns
T31.82  Burns involving 80-89% of body surface with 20-29% third degree burns
T31.83  Burns involving 80-89% of body surface with 30-39% third degree burns
T31.84  Burns involving 80-89% of body surface with 40-49% third degree burns
T31.85  Burns involving 80-89% of body surface with 50-59% third degree burns
T31.86  Burns involving 80-89% of body surface with 60-69% third degree burns
T31.87  Burns involving 80-89% of body surface with 70-79% third degree burns
T31.88  Burns involving 80-89% of body surface with 80-89% third degree burns
T31.90  Burns involving 90% or more of body surface with 0% to 9% third degree burns
T31.91  Burns involving 90% or more of body surface with 10-19% third degree burns
T31.92  Burns involving 90% or more of body surface with 20-29% third degree burns
T31.93  Burns involving 90% or more of body surface with 30-39% third degree burns
T31.94  Burns involving 90% or more of body surface with 40-49% third degree burns
T31.95  Burns involving 90% or more of body surface with 50-59% third degree burns
T31.96  Burns involving 90% or more of body surface with 60-69% third degree burns
T31.97  Burns involving 90% or more of body surface with 70-79% third degree burns
T31.98  Burns involving 90% or more of body surface with 80-89% third degree burns
T31.99  Burns involving 90% or more of body surface with 90% or more third degree burns
T32.0  Corrosions involving less than 10% of body surface
T32.10 Corrosions involving 10-19% of body surface with 0% to 9% third degree corrosion
T32.11 Corrosions involving 10-19% of body surface with 10-19% third degree corrosion
T32.20 Corrosions involving 20-29% of body surface with 0% to 9% third degree corrosion
T32.21 Corrosions involving 20-29% of body surface with 10-19% third degree corrosion
T32.22 Corrosions involving 20-29% of body surface with 20-29% third degree corrosion
T32.30 Corrosions involving 30-39% of body surface with 0% to 9% third degree corrosion
T32.31 Corrosions involving 30-39% of body surface with 10-19% third degree corrosion
T32.32 Corrosions involving 30-39% of body surface with 20-29% third degree corrosion
T32.33 Corrosions involving 30-39% of body surface with 30-39% third degree corrosion
T32.40 Corrosions involving 40-49% of body surface with 0% to 9% third degree corrosion
T32.41 Corrosions involving 40-49% of body surface with 10-19% third degree corrosion
T32.42 Corrosions involving 40-49% of body surface with 20-29% third degree corrosion
T32.43 Corrosions involving 40-49% of body surface with 30-39% third degree corrosion
T32.44 Corrosions involving 40-49% of body surface with 40-49% third degree corrosion
T32.50 Corrosions involving 50-59% of body surface with 0% to 9% third degree corrosion
T32.51 Corrosions involving 50-59% of body surface with 10-19% third degree corrosion
T32.52 Corrosions involving 50-59% of body surface with 20-29% third degree corrosion
T32.53 Corrosions involving 50-59% of body surface with 30-39% third degree corrosion
T32.54 Corrosions involving 50-59% of body surface with 40-49% third degree corrosion
T32.55 Corrosions involving 50-59% of body surface with 50-59% third degree corrosion
T32.60 Corrosions involving 60-69% of body surface with 0% to 9% third degree corrosion
T32.61 Corrosions involving 60-69% of body surface with 10-19% third degree corrosion
T32.62 Corrosions involving 60-69% of body surface with 20-29% third degree corrosion
T32.63 Corrosions involving 60-69% of body surface with 30-39% third degree corrosion
T32.64 Corrosions involving 60-69% of body surface with 40-49% third degree corrosion

Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association.
Contains Public Information
T32.65 Corrosions involving 60-69% of body surface with 50-59% third degree corrosion
T32.66 Corrosions involving 60-69% of body surface with 60-69% third degree corrosion
T32.70 Corrosions involving 70-79% of body surface with 0% to 9% third degree corrosion
T32.71 Corrosions involving 70-79% of body surface with 10-19% third degree corrosion
T32.72 Corrosions involving 70-79% of body surface with 20-29% third degree corrosion
T32.73 Corrosions involving 70-79% of body surface with 30-39% third degree corrosion
T32.74 Corrosions involving 70-79% of body surface with 40-49% third degree corrosion
T32.75 Corrosions involving 70-79% of body surface with 50-59% third degree corrosion
T32.76 Corrosions involving 70-79% of body surface with 60-69% third degree corrosion
T32.77 Corrosions involving 70-79% of body surface with 70-79% third degree corrosion
T32.80 Corrosions involving 80-89% of body surface with 0% to 9% third degree corrosion
T32.81 Corrosions involving 80-89% of body surface with 10-19% third degree corrosion
T32.82 Corrosions involving 80-89% of body surface with 20-29% third degree corrosion
T32.83 Corrosions involving 80-89% of body surface with 30-39% third degree corrosion
T32.84 Corrosions involving 80-89% of body surface with 40-49% third degree corrosion
T32.85 Corrosions involving 80-89% of body surface with 50-59% third degree corrosion
T32.86 Corrosions involving 80-89% of body surface with 60-69% third degree corrosion
T32.87 Corrosions involving 80-89% of body surface with 70-79% third degree corrosion
T32.88 Corrosions involving 80-89% of body surface with 80-89% third degree corrosion
T32.90 Corrosions involving 90% or more of body surface with 0% to 9% third degree corrosion
T32.91 Corrosions involving 90% or more of body surface with 10-19% third degree corrosion
T32.92 Corrosions involving 90% or more of body surface with 20-29% third degree corrosion
T32.93 Corrosions involving 90% or more of body surface with 30-39% third degree corrosion
T32.94 Corrosions involving 90% or more of body surface with 40-49% third degree corrosion
T32.95 Corrosions involving 90% or more of body surface with 50-59% third degree corrosion
T32.96 Corrosions involving 90% or more of body surface with 60-69% third degree corrosion
T32.97 Corrosions involving 90% or more of body surface with 70-79% third degree corrosion
T32.98 Corrosions involving 90% or more of body surface with 80-89% third degree corrosion
T32.99 Corrosions involving 90% or more of body surface with 90% or more third degree corrosion
Z15.01 Genetic susceptibility to malignant neoplasm of breast
Z85.3 Personal history of malignant neoplasm of breast
Z90.11 Acquired absence of right breast and nipple
Z90.12 Acquired absence of left breast and nipple
Z90.13 Acquired absence of bilateral breasts and nipples

<table>
<thead>
<tr>
<th></th>
<th>REVISIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>04-30-2015</td>
<td>Policy published 03-31-2015</td>
</tr>
<tr>
<td></td>
<td>Description section updated</td>
</tr>
<tr>
<td></td>
<td>In Policy section:</td>
</tr>
<tr>
<td></td>
<td>▪ In Item A added &quot;allogeneic&quot; and &quot;products*&quot; to read, &quot;...using the following allogeneic acellular dermal matrix products* may be considered medically necessary...&quot;</td>
</tr>
<tr>
<td></td>
<td>▪ In Item A added the following four medically necessary skin substitutes: AlloMax, DermaMatrix, FlexHD, and GraftJacket.</td>
</tr>
<tr>
<td></td>
<td>▪ In Item B added the following medically necessary skin substitute: Epifix.</td>
</tr>
<tr>
<td></td>
<td>▪ In Item G moved the following experimental / investigational skin and soft tissue substitutes to be medically necessary: AlloMax, DermaMatrix Acellular Dermis, EpiFix (Q4131) (Q4145), FlexHD Acellular Hydrated Dermis (Q4128), GraftJacket (Q4107).</td>
</tr>
<tr>
<td></td>
<td>▪ In Item G added the following experimental / investigational skin and soft tissue substitutes: ACell UBM Hydatied Wound Dressing, ACell UBM Lyophilized Wound Dressing, Affinity (Q4159), Allowrap (Q4150), Alphaplex with MariGen Omega3, AmnioBand (Q4151), Aongen Collagen Matrix, Atlas Wound Matrix, Avagen Wound Dressing, Biovance (Q4154), Clarix Flo, Collagen Sponge (Innocoll), Collagen Wound</td>
</tr>
</tbody>
</table>

Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information
### REVISIONS

Dressing (Oasis Research), Collaguard, CollaSorb, CollaWound, Collexa, Collieva, Coreleader Colla-Pad, Dermadapt Wound Dressing, Dermapure (Q4152), Dermavest (Q4153), DressSkin, FortaDerm Wound Dressing (C9349), GUARDIAN (Q4151), HA Absorbent Wound Dressing, Helicoll, Hyalomatrix (Laserskin), Jaloskin, MariGen (Q4158), Matrix Collagen Wound Dressing, Neox Flo (Q4155), Primatrix Dermal Repair Scaffold, Puros Dermis, Repliform, Revitalon (Q4157), SIS Wound Dressing II, Solana, SS Matrix, Stimulen Collagen, Suprathel, TheraForm Standard/Sheet.

- In Item G removed reference to the following experimental / investigational skin and soft tissue substitutes: Allograft, Allopatch, Alloskin AC (Q4141), AmnioExCel (Q4137), Aminomatrix (Q4139), Architect Extracellular Matrix (Q4147), Artelon, Arthres GraftRope, Avotermín, BioDfence Dryflex (Q4138), Biostat Biolyx, Biotape, C-QUR, CollaFix, Collamend, CorMatrix Patch, Cuffpatch, Cymetra Injectable Allograft (Q4112), Dermacell (Q4122), DermaClose RC Continuous External Tissue Expander, DuraGen Plus, EpiDex, Evicel, GraftJacket Regenerative Tissue Matrix, Inforce, Integra Neural Wrap, Integra Matrix Wound Dressing (Q4108), Medeor, Meso BioMatrix, Neuragen, NeuraWrap, Neuroflex, NeuroMatrix Collagen Nerve Cuff (C9361), NeuroMend Collagen Nerve Wrap (C9361), NuCel, OrthADAPT Biom implant, Ovation, Pelvicel, Pelvisoft, Peri-Strips Dry, Permacol Biologic Implant, PriMatrix Acellular Dermal Tissue Matrix, Promogran, PTFE felt, Puracol, Seamguard, SportMatrix, SportMesh, Strattice Tissue Matrix, TenSIX (Q4146), TheraSkin, TissueMend (Q4109), X-Repair, XenMatrix

(Removal of these products does not mean they are considered medically necessary, rather they were not considered to be appropriate for this policy at this time)

Rational section updated

In Coding section:
- Added HCPCS Codes: C9349, Q4150, Q4151, Q4152, Q4153, Q4154, Q4155, Q4157, Q4158, Q4159, Q4160.
- Removed HCPCS Codes: C9355, C9361, C9367, Q4108, Q4109, Q4122, Q4137, Q4138, Q4139, Q4141, Q4142, Q4146, Q4147.
- Revised HCPCS Codes: Q4113, Q4119, Q4123, Q4124, Q4125, Q4127, Q4128, Q4129, Q4130, Q4140, Q4143, Q4148

In Revision section:
- Removed revision details for: 08-03-2010, 02-01-2012.

References updated

05-01-2016 Published 03-31-2016. Effective 05-01-2016

Description section updated

In Policy section:
- In Item B added "Integra Dermal Regeneration Template (Q4105)"
- In Item B added "Biovance (Q4154)" and "Grafix (Q4132) (Q4133)" and "(Amniotic Membrane Grafts*)" to read "Biovance (Q4154), Grafix (Q4131) (Q4145), Grafix (Q4132) (Q4133) (Amniotic Membrane Grafts*)"
- In Item G removed the following products from the E/I list: "AmnioBand (Q4151), Biovance (Q4154), Grafix Core (Q4132), Grafix Prime (Q4133), NEOX 1K (Q4148), Solana"
- In Item G removed "Unite" to read "TheraSkin (Q4121)"
- In Item G added the following products to the E/I list (these are products in the HCPCS code list that were not referenced in the policy statement): "AlloSkin AC, per sq cm (Q4141), AmnioExcel, per sq cm (Q4137), Amniogen-45, Amniogen-200, per sq cm (Q4163), AmnioMatrix, injectable, 1 cc (Q4139), AmnioPro, per sq cm (Q4163), Architect, Architect PX, or Architect FX, extracellular matrix, per sq cm (Q4147), Bio-ConneKt wound matrix, per sq cm (Q4161), BioDFexCel, per sq cm (Q4137), BioDFence DryFlex, per sq cm (Q4138), BioDMatrix, injectable, 1 cc (Q4139), BioSkin, per sq cm (Q4163), BioRenew, per sq cm (Q4163), DermACELL, per sq cm (Q4122), Integra matrix, per sq cm (Q4108),
# REVISIONS

Keramatrix, per sq cm (Q4165), Neox 100, per sq cm (Q4156), Plurivest, per sq cm (Q4153), Tensix, per sq cm (Q4146), WoundEx, per sq cm (Q4163), XCM biologic tissue matrix, per sq cm (Q4142)

- In Item G added "(Q4164) to read "Helicoll (Q4164)"

## Rationale section updated

In Coding section:
- Added HCPCS Codes: Q4161, Q4163, Q4164, Q4165 (Effective January 1, 2016)
- Added HCPCS Codes: Q4108, Q4122, Q4137, Q4138, Q4139, Q4141, Q4142, Q4146, Q4147, Q4156
- Revised HCPCS Code Nomenclature: Q4153 (Effective January 1, 2016)
- Revised HCPCS Code Nomenclature: C9349

## References updated

03-20-2017

In Title section added "See Also: Amniotic Membrane and Amniotic Fluid medical policy"

## Description section updated

In Policy section:
- In Item A added "AlloMend"
- In Item B added "AlloPatch*" and removed "Biovance (Q4154), Epifix (Q4131) (Q4145), Grafix (Q4132) (Q4133) (Amniotic Membrane Grafts*)"
- In Item 3 removed "TransCyte**"
- Updated asterisk Key
- In Item G moved the following E/I skin and soft tissue substitute to be medically necessary: AlloPatch HD (Q4128).
- In Item G revised the following E/I skin and soft tissue substitutes: combined "ACell UBM Lyophilized Wound Dressing" and "ACell UBM Hydrated Wound Dressing" to read "ACell UBM Hydrated / Lyophilized Wound Dressing"; "Architect, Architect PX, or Architect FX, extracellular matrix" to "Architect ECM, PX, FX"; "BioDfenceDryFlex" to "BioDryFlex"; revised "CellerateRX" to "CellerateRX (CRXa)"; "Hyalomatrix (LaserSkin)" to "Hyalomatrix"; "MariGen" to "MariGen / Kerecis Omega3"; "Oasis Ultra Tri-Layer Matrix" to "Oasis Ultra"; "TenSix" to "TenSix Acellular Dermal Matrix"
- In Item G added the following E/I skin and soft tissue substitutes: AxoGuard Nerve Protector (AxoGen), CollaCare, CollaCare Dental, CollaMend, Cytal, DermaSpan, ExpressGraft, FlexiGraft, Integra Omnimold, Miroderm biologic wound matrix, NeoForm, NuCel, Oasis Wound Matrix, Pelvicol / PelviSoft, PuraPly Wound Matrix, PuraPly AM (Antimicrobial Wound Matrix), RegenePro, TissueMend, TruSkin, XenMatrix AB
- In Item G removed the following E/I skin and soft tissue substitutes: Affinity, AlloPatch HD, Allowrap, Alphaplex with MariGen Omega3, AmnioExcel, AmnioFix, Amniogen-45, Amniogen-200, AmnioMatrix, injectable, AmnioPro, Avulta Plus, BioDEXCel, BioDfence/BioDFactor, BioDFMatrix, injectable, BioSkin, BioRenew, Clarix Flo, Collagen Sponge (Innocoll), CollaSorb, CRXa, Dermavest, FortaDerm Wound Dressing, GUARDIAN, HA Absorbent Wound Dressing, Jaloskin, MatrisTem Burn Matrix, MatrisTem Wound Matrix, Matrix Collagen Wound Dressing, MediHoney, Neo 100, Neo Flo, NuShield, Plurivest, Revitalon, SIS Wound Dressing II, SS Matrix, Stimulen Collagen, Unite Biomatrix, WoundEx
- Policy Guidelines added

## Rationale section updated

In Coding section:
- Revised HCPCS code nomenclature: Q4105
- Added HCPCS codes: Q4166, Q4167, Q4172, Q4175 (Effective 01-01-2017)
- Removed HCPCS codes: C9349, Q4119, Q4120, Q4129 (Termed 12-31-2016)
- Removed HCPCS codes: Q4131, Q4132, Q4133, Q4137, Q4138, Q4139, Q4140, Q4145, Q4148, Q4150, Q4151, Q4153, Q4154, Q4155, Q4156, Q4157, Q4159, Q4160, Q4163
## REVISIONS

### In Revision section:
- Removed revision details for the following dates: 01-15-2016, 12-12-2013, 01-01-2014.

### References updated

### 04-19-2017
- In Policy section:
  - Removed "CellerateRX (CRXa)" from the policy due to the product not being a skin or soft tissue substitute and not relevant to the policy.

### 07-18-2018
- Description section updated

### In Policy section:
- In Item A added "Cortiva", "DermACELL", and "FlexHDPliable"
- In Items B and E updated "Integra Derma Regeneration Template" to "Integra Omnigraft Dermal Regeneration Matrix (also known as Omnigraft)"
- In Item B added "Integra Flowable Wound Matrix"
- In Item G removed "BioDDryFlex (Q4138), DermACEll, per sq cm (Q4122), Integra Flowable Wound Matrix (Q4114), Integra Omnigraft (Q4105), Oasis Wound Matrix (Q4102)"
- In Item G added "Kerecis (Q4158), NeoPatch, per sq cm (Q4176), FlowerAmnioFlo, 0.1 cc (Q4177), FlowerAmnioPatch, per sq cm (Q4178), FlowerDerm, per sq cm (Q4179), Revita, per sq cm (Q4180), Amnio Wound, per sq cm (Q4181), TransCyte, per sq cm (Q4182)"
- In Item G revised "Biobrane" to "Biobrane / Biobrane-L" and "Cymetra (Q4112)" to "Cymetra (Micronized AlloDerm) (Q4112)"

### Rationale section updated

### In Coding section:
- Added CPT Codes: 15200, 15201, 15220, 15221, 15240, 15241, 15260, 15261
- Added HCPCS Codes: Q4176, Q4177, Q4178, Q4179, Q4180, Q4181, Q4182 (Effective January 1, 2018)

### References updated

### 01-01-2019
- In Policy section:
  - In Item G removed the following experimental / investigational products:
    "PuraPly Wound Matrix (previously FortaDerm) (Q4172)
    PuraPly AM (Antimicrobial Wound Matrix) (Q4172)"

  - and added the following experimental / investigational products:
    "20. Coll-e-derm, per square centimeter (Q4193)
    29. Derma-gide, per square centimeter (Q4203)
    53. Keroxx (2.5g/cc), 1cc (Q4202)
    70. Puraply, per square centimeter (Q4195)
    71. Puraply am, per square centimeter (Q4196)
    72. Puraply xt, per square centimeter (Q4197)
    78. Skin te, per square centimeter (Q4200)"

### In Coding section:
- Added HCPCS Codes: Q4193, Q4195, Q4196, Q4197, Q4200, Q4202, Q4203
- Removed HCPCS Code: Q4172

### 11-26-2019
- Description section updated

### In Policy section:
- In Item A moved AlloMax to be with Cortiva to read "Cortiva [AlloMax]"
- In Item E w removed "Omnigraft", and "Matrix (also known as Omnigraft and added "Template" to read "Integra Dermal Regeneration Template (Q4105)"

  - In Item G removed "FlexiGraft"; added "BellaCell HD or Surederm, per square centimeter (Q4220)", "MyOwn skin, includes harvesting and preparation procedures, per square centimeter (Q4226)", "Progenamatrix, per square centimeter (Q4222)"); and revised "Puraply" to read "Puraply Wound Matrix (previously FortaDerm™), per square
**REVISIONS**

- “centimeter (Q4195)” to read “Puraply AM (Antimicrobial Wound Matrix), per square centimeter (Q4196)”
- Rationale section updated
- In Coding Section:
  - Added HCPCS Codes (Effective 10-01-2019): Q4220, Q4222, Q4226
  - Revised HCPCS Codes: Q4122, Q4158, Q4165
- Added ICD-10 Codes (Effective 10-01-2019): L89.016, L89.026, L89.116, L89.126, L89.136, L89.146, L89.156, L89.216, L89.226, L89.316, L89.326, L89.46, L89.516, L89.526, L89.616, L89.626, L89.816, L89.896
- References updated

**REFERENCES**


Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information


41. Karr JC. Retrospective comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf). *Advances in skin & wound care*. Mar 2011;24(3):119-125. PMID 21326023


Blue Cross and Blue Shield of Kansas is an independent licensee of the Blue Cross Blue Shield Association

Contains Public Information


**Other References:**
